0001615774-18-007923.txt : 20180813 0001615774-18-007923.hdr.sgml : 20180813 20180813162033 ACCESSION NUMBER: 0001615774-18-007923 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20180630 FILED AS OF DATE: 20180813 DATE AS OF CHANGE: 20180813 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ATOSSA GENETICS INC CENTRAL INDEX KEY: 0001488039 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 264753208 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35610 FILM NUMBER: 181012489 BUSINESS ADDRESS: STREET 1: 107 SPRING STREET CITY: SEATTLE STATE: WA ZIP: 98104 BUSINESS PHONE: 206.588.0256 MAIL ADDRESS: STREET 1: 107 SPRING STREET CITY: SEATTLE STATE: WA ZIP: 98104 10-Q 1 s111760_10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2018

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

Commission file number: 001-35610

ATOSSA GENETICS INC.

(Exact name of registrant as specified in its charter)

Delaware		26-4753208
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

107 Spring Street		98104
Seattle, WA		(Zip Code)
(Address of principal executive offices)

Registrant’s telephone number, including area code: (206) 325-6086

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer ☐

Smaller reporting company ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares of the registrant’s common stock, $0.18 par value per share, outstanding at August 10, 2018 was 5,069,559.

ATOSSA GENETICS INC.

FORM 10-Q

QUARTERLY REPORT

INDEX

PART I. FINANCIAL INFORMATION		3

ITEM 1.	Condensed Consolidated Financial Statements – Unaudited	3

	Condensed Consolidated Balance Sheets as of June 30, 2018 and December 31, 2017	3

	Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2018 and 2017	4

	Condensed Consolidated Statement of Stockholders’ Equity for the six months ended June 30, 2018	5

	Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2018 and 2017	6

	Notes to Condensed Consolidated Financial Statements	7

ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	21

ITEM 3	Quantitative and Qualitative Disclosures about Market Risk	28

ITEM 4.	Controls and Procedures	28

PART II. OTHER INFORMATION		29

ITEM 1.	Legal Proceedings	29

ITEM 1A.	Risk Factors	31

ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	31

ITEM 3.	Defaults upon Senior Securities	32

ITEM 4.	Mine Safety Disclosures	32

ITEM 5.	Other Information	32

ITEM 6.	Exhibits	32

SIGNATURES		33

PART I. FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

ATOSSA GENETICS INC.

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

	June 30,			December 31,
	2018			2017
Assets
Current assets
Cash and cash equivalents	$	15,236,736		$	7,217,469
Restricted cash		55,000			55,000
Prepaid expenses		440,389			250,944
Research and development tax rebate receivable		626,011			358,277
Other current assets		50,035			16,344
Total current assets		16,408,171			7,898,034

Furniture and equipment, net		60,926			11,467
Intangible assets, net		59,882			75,686
Other assets		48,867			178,907
Total assets	$	16,577,846		$	8,164,094

Liabilities and Stockholders’ Equity

Current liabilities
Accounts payable	$	191,217		$	334,901
Accrued expenses		286,713			90,105
Payroll liabilities		952,657			784,867
Stock-based compensation liability		1,557,163
Other current liabilities		23,331			15,534
Total current liabilities		3,011,081			1,225,407

Commitments and contingencies (note 11)

Stockholders’ equity
Preferred stock - $0.001 par value; 10,000,000 shares authorized, consisting of: Series A convertible preferred stock-$0.001 par value; 4,000 shares authorized, and 0 shares outstanding as of June 30, 2018 and December 31, 2017; Series B convertible preferred stock- $0.001 par value; 25,000 and 0 shares authorized, and 5,802 and 0 shares issued and outstanding, as of June 30, 2018 and December 31, 2017, respectively		6
Additional paid-in capital-Series B convertible preferred stock		5,234,116
Common stock - $0.18 par value; 175,000,000 shares authorized, 4,874,099 and 2,651,952 shares issued and outstanding, as of June 30, 2018 and December 31, 2017, respectively		877,329			477,342
Additional paid-in capital		78,898,602			71,887,674
Accumulated deficit		(71,443,288	)		(65,426,329	)
Total stockholders’ equity		13,566,765			6,938,687

Total liabilities and stockholders’ equity	$	16,577,846		$	8,164,094

The accompanying notes are an integral part of these condensed consolidated financial statements.

ATOSSA GENETICS INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

	For the Three Months Ended June 30,						For The Six Months Ended June 30,

		2018			2017			2018			2017
Operating expenses:
Research and development	$	1,467,736		$	824,094		$	1,938,712		$	1,368,396
General and administrative		2,674,920			1,072,169			4,078,385			2,231,458
Total operating expenses		4,142,656			1,896,263			6,017,097			3,599,854
Operating loss		(4,142,656	)		(1,896,263	)		(6,017,097	)		(3,599,854	)
Change in fair value of common stock warrants					(152,447	)					(152,447	)
Warrant financing expense					(192,817	)					(192,817	)
Other income		79			38			138			75
Loss before income taxes		(4,142,577	)		(2,241,489	)		(6,016,959	)		(3,945,043	)
Income taxes
Net loss	$	(4,142,577	)	$	(2,241,489	)	$	(6,016,959	)	$	(3,945,043	)
Deemed dividends attributable to preferred stock		(4,782,100	)		(2,568,132	)		(4,782,100	)		(2,568,132	)
Net loss applicable to common stockholders	$	(8,924,677	)	$	(4,809,621	)	$	(10,799,059	)	$	(6,513,175	)
Loss per common share - basic and diluted	$	(2.90	)	$	(7.72	)	$	(3.77	)	$	(13.85	)
Weighted average shares outstanding, basic and diluted		3,073,803			623,004			2,864,033			470,139

The accompanying notes are an integral part of these condensed consolidated financial statements.

ATOSSA GENETICS INC.

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY

(UNAUDITED)

	Series B Convertible Preferred Stock									Common Stock										Total
							Additional							Additional			Accumulated			Stockholders’
	Shares			Amount			Paid-in Capital			Shares		Amount		Paid-in Capital			Deficit			Equity
Balance at December 31, 2017				$			$				2,651,952	$	477,342	$	71,887,674		$	(65,426,329	)	$	6,938,687

Issuance of Series B convertible preferred stock, net of issuance costs of $1,333,449		13,624			14			12,290,537													12,290,551
Allocation of Series B convertible preferred stock to beneficial conversion feature								(4,782,100)							4,782,100
Deemed Dividend on Series B convertible preferred stock								4,782,100							(4,782,100	)
Conversion of Series B convertible preferred stock to common stock		(7,822	)		(8	)		(7,056,421	)		2,222,147		399,987		6,656,442

Amortization of commitment shares															(39,703	)					(39,703	)
Compensation cost for stock options granted to executives and employees															394,189						394,189
Net loss																		(6,016,959	)		(6,016,959	)
Balance at June 30, 2018		5,802		$	6		$	5,234,116			4,874,099	$	877,329	$	78,898,602		$	(71,443,288	)	$	13,566,765

The accompanying notes are an integral part of these condensed consolidated financial statements.

ATOSSA GENETICS INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	For the Six Months Ended June 30,
	2018			2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(6,016,959	)	$	(3,945,043	)
Compensation cost for stock options granted		394,189			336,115
Loss on disposal of intangible asset					17,695
Change in stock-based compensation liability		1,557,163
Depreciation and amortization		17,838			73,193
Change in fair value of common stock warrants					152,447
Warrant financing expense					192,817
Changes in operating assets and liabilities:
Prepaid expenses		(189,445	)		(56,769	)
Research and development tax rebate receivable		(267,734	)
Other assets		56,644			25,831
Accounts payable		(143,684	)		241,491	)
Payroll liabilities		167,790			(287,479	)
Accrued expenses		196,608			27,053
Other current liabilities		7,797			13,074
Net cash used in operating activities		(4,219,793	)		(3,209,575	)

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of furniture and equipment		(51,491	)
Net cash used in investing activities		(51,491	)

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of Class A and Class B Units, net of issuance costs					3,871,636
Proceeds from issuance of Series B convertible preferred stock, net of issuance costs		12,290,551
Net cash provided by financing activities		12,290,551			3,871,636

NET INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH		8,019,267			662,061
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, BEGINNING BALANCE		7,272,469			3,082,962
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, ENDING BALANCE	$	15,291,736		$	3,745,023

NONCASH INVESTING AND FINANCING ACTIVITIES
Common stock issued for cashless exercise of common stock warrants	$			$	900,488
Amount receivable for warrant exercise					2,600
Allocation of Class A and Class B Unit proceeds to warrant liability					1,612,416
Amortization of commitment shares	$	39,703		$	39,705

The accompanying notes are an integral part of these condensed consolidated financial statements.

ATOSSA GENETICS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 1: NATURE OF OPERATIONS

Atossa Genetics Inc. (the “Company”) was incorporated on April 30, 2009 in the State of Delaware. The Company was formed to develop and market medical devices, laboratory tests and therapeutics to address breast health conditions. The Company’s fiscal year ends on December 31. The Company is focused on development of its pharmaceutical and drug delivery programs.

NOTE 2: GOING CONCERN

The Company’s consolidated financial statements are prepared using Generally Accepted Accounting Principles in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses and negative operating cash flows since inception. For the six months ended June 30, 2018, the Company recorded a net loss of approximately $6.0 million and used approximately $4.2 million of cash in operating activities. As of June 30, 2018 the Company had approximately $15.2 million in cash and cash equivalents and working capital of approximately $13.4 million. The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs and allow it to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. The Company can give no assurances that any additional capital that it is able to obtain, if any, will be sufficient to meet its needs, or that any such capital will be obtained on acceptable terms. If the Company is unable to obtain adequate capital, it could be forced to cease operations or substantially curtail its activities. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities should the Company be unable to continue as a going concern.

Management’s plan to continue as a going concern includes obtaining additional capital resources. Management’s plans to obtain such resources for the Company include obtaining capital from the sale of its equity securities, potential exercise of outstanding warrants, and short-term borrowings from banks, stockholders or other related parties, if needed. However, management cannot provide any assurance that the Company will be successful in accomplishing any of its plans.

As of the date of filing this report, we expect that our existing resources will be sufficient to fund our planned operations for the next 12 to 18 months; however, additional capital resources will be needed to fund operations longer-term.

The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraphs and eventually to secure other sources of financing and attain profitable operations.

NOTE 3: SUMMARY OF ACCOUNTING POLICIES

Basis of Presentation:

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. They do not include all information and notes required by GAAP for complete financial statements. However, except as disclosed herein, there has been no material change in the information disclosed in the Notes to Consolidated Financial Statements included in the Annual Report on Form 10-K of the Company for the year ended December 31, 2017.

In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018.

On April 20, 2018, the Company completed a 1-for-12 reverse stock split of the shares of the Company’s common stock (the “Reverse Stock Split”). As a result of the Reverse Stock Split, every 12 shares of issued and outstanding common stock were combined into one issued and outstanding share of common stock, and the par value per share was changed to $0.18 per share. The number of authorized shares of common stock was not reduced as a result of the Reverse Stock Split. The Company’s common stock began trading on a reverse stock split-adjusted basis on April 20, 2018. All share and per share data included in this report has been retroactively restated to reflect the Reverse Stock Split.

Use of Estimates:

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Recently Issued Accounting Pronouncements:

In February 2016, Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Lease Accounting Topic 842. This ASU requires a lessee to recognize lease assets and liabilities on the balance sheet for all arrangements with terms longer than 12 months. The new standard applies a right-of-use (ROU) model that requires a lessee to record, for all leases with a lease term of more than 12 months, an asset representing its right to use the underlying asset for the lease term and a liability to make lease payments. The lease term is the non-cancellable period of the lease, and includes both periods covered by an option to extend the lease, if the lessee is reasonably certain to exercise that option, and periods covered by an option to terminate the lease, if the lessee is reasonably certain not to exercise that termination option. For leases with a lease term of 12 months or less, a practical expedient is available whereby a lessee may elect, by class of underlying asset, not to recognize an ROU asset or lease liability. A lessee making this accounting policy election would recognize lease expense over the term of the lease, generally in a straight-line pattern. The lessor accounting remains largely consistent with existing GAAP. The new standard takes effect in 2019 for public business entities. The Company has not adopted the provisions of ASU No. 2016-02 and is currently evaluating the impact of adopting ASU 2016-02 on its consolidated financial statements.

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows, amending the presentation of restricted cash within the statement of cash flows. The new guidance requires that restricted cash be included within cash and cash equivalents on the statement of cash flows. The Company adopted the provisions of ASU No. 2016-18 as of January 1, 2018 and has included restricted cash with cash and cash equivalents on the accompanying statement of cash flows, including reclassifying 2017 balances. For the three and six months ended June 30, 2018 and June 30, 2017, we included $55,000 of restricted cash in cash and cash equivalents on the statement of cash flows. The restricted cash represents a required deposit for the Company credit card and is restricted until the Company no longer has the credit card or the limit changes on the credit card.

In July 2017, the FASB issued ASU 2017-11, Accounting for Certain Financial Instruments with Down Round Features and Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Part I of this ASU addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of future equity offerings. Current accounting guidance requires financial instruments with down round features to be accounted for at fair value. Part II of the Update applies only to nonpublic companies and is therefore not applicable to the Company. The amendments in Part I of the Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. This Update is effective for public entities for fiscal years beginning after December 15, 2018. Early adoption is permitted. The Company early adopted the provisions of ASU No. 2017-11 as of January 1, 2018. As the Company does not have any financial instruments with down round features outstanding as of June 30, 2018, this ASU did not have a material impact on the financial statements upon adoption.

In June 2018, The FASB issued ASU 2018-07, Compensation-Stock Compensation Improvements to Nonemployee Share Based Payment Accounting. This ASU simplifies several aspects of the accounting for non-employee share-based payment transactions resulting from expanding the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide financing to the issuer or was granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers. This update is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted. The Company early adopted the provisions of ASU No. 2018-17 as of April 1, 2018 and it did not have a material impact on the financial statements upon adoption.

NOTE 4: PREPAID EXPENSES

Prepaid expenses consisted of the following:

	June 30, 2018		December 31, 2017
Prepaid insurance	$	148,284	$	125,056
Retainer and security deposits		16,718		14,218
Professional services		110,094		97,788
Prepaid research and development		115,014
Financial exchange fees		27,500
Other		22,779		13,882
Total prepaid expenses	$	440,389	$	250,944

NOTE 5: RESEARCH AND DEVELOPMENT TAX REBATE RECEIVABLE

On May 23, 2017 Atossa formed a wholly-owned subsidiary in Australia called Atossa Genetics AUS Pty Ltd. The purpose of this subsidiary is to perform research and development activities (“R&D”) including our Phase 1 and Phase 2 endoxifen clinical trials. Australia offers an R&D cash rebate of $0.435 per dollar spent on qualified R&D activities incurred in the country. For the six months ended June 30, 2018, the Company incurred qualified R&D expenses of approximately $616,000, resulting in an increase to the R&D rebate receivable of approximately $268,000 from the year ended December 31, 2017 balance, and a corresponding offset to R&D expenses in the same amount. At June 30, 2018, we had a total R&D rebate receivable of approximately $626,000.

NOTE 6: PAYROLL LIABILITIES

Payroll liabilities consisted of the following:

	June 30, 2018		December 31, 2017
Accrued bonus payable	$	662,512	$	566,000
Accrued vacation		167,174		147,861
Accrued payroll liabilities		122,971		71,006
Total payroll liabilities	$	952,657	$	784,867

NOTE 7: STOCKHOLDERS’ EQUITY

The Company is authorized to issue a total of 185,000,000 shares of stock consisting of 175,000,000 shares of common stock, par value $0.18 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share. The Company has designated 750,000 shares of Series A junior participating preferred stock, par value $0.001 per share, 4,000 shares of Series A convertible preferred stock, par value $0.001 per share, and 25,000 shares of Series B convertible preferred stock through the filings of certificates of designation with the Delaware Secretary of State. No shares of Series A junior participating preferred stock and no shares of Series A convertible preferred stock are issued and outstanding as of June 30, 2018.

On May 19, 2014, the Company adopted a stockholder rights agreement which provides that all stockholders of record on May 26, 2014 received a non-taxable distribution of one preferred stock purchase right for each share of the Company’s common stock held by such stockholder. Each right is attached to and trades with the associated share of common stock. The rights will become exercisable only if one of the following occurs: (1) a person becomes an “Acquiring Person” by acquiring beneficial ownership of 15% or more of the Company’s common stock (or, in the case of a person who beneficially owned 15% or more of the Company’s common stock on the date the stockholder rights agreement was executed, by acquiring beneficial ownership of additional shares representing 2.0% of the Company’s common stock then outstanding (excluding compensatory arrangements)), or (2) a person commences a tender offer that, if consummated, would result in such person becoming an Acquiring Person. If a person becomes an Acquiring Person, each right will entitle the holder, other than the Acquiring Person and certain related parties, to purchase a number of shares of the Company’s common stock with a market value that equals twice the exercise price of the right. The initial exercise price of each right is $15.00, so each holder (other than the Acquiring Person and certain related parties) exercising a right would be entitled to receive $30.00 worth of the Company’s common stock. If the Company is acquired in a merger or similar business combination transaction at any time after a person has become an Acquiring Person, each holder of a right (other than the Acquiring Person and certain related parties) will be entitled to purchase a similar amount of stock of the acquiring entity.

2018 Subscription Rights Offering of Units Consisting of Series B Convertible Preferred Stock and Warrants

On May 9, 2018, the Company’s Registration Statement on Form S-1 with the Securities and Exchange Commission was declared effective to offer subscription rights to purchase up to 25,000 units at $1,000 per unit with each unit consisting of one share of Series B convertible preferred stock and warrants to purchase 284 shares of common stock.

On May 29, 2018, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series B convertible preferred stock with the Delaware Secretary of State creating a new series of its authorized preferred stock, par value $0.001 per share, designated as the Series B convertible preferred stock. The number of shares initially constituting the Series B preferred stock was set at 25,000 shares.

On May 30, 2018, the Company completed its previously announced rights offering pursuant to which the Company sold an aggregate of 13,624 units consisting of an aggregate of 13,624 shares of Series B convertible preferred stock and 3,869,216 warrants, with each warrant exercisable for one share of common stock at an exercise price of $4.048 per share (the “2018 Warrants”), resulting in net proceeds to the Company of approximately $12.3 million, after deducting expenses relating to the rights offering, including dealer-manager fees and expenses, and excluding any proceeds received upon exercise of any warrants.

Series B Convertible Preferred Stock.

The terms and provisions of our Series B convertible preferred stock are:

Conversion. Each share of Series B convertible preferred stock is convertible at our option at any time on or after the first anniversary of the closing of the rights offering or at the option of the holder at any time, into the number of shares of our common stock determined by dividing the $1,000 stated value per share of the Series B convertible preferred stock by a conversion price of $3.52 per share. In addition, the conversion price per share is subject to adjustment for stock dividends, distributions, subdivisions, combinations or reclassifications. Subject to limited exceptions, a holder of the Series B convertible preferred stock will not have the right to convert any portion of the Series B convertible preferred stock to the extent that, after giving effect to the conversion, the holder, together with its affiliates, would beneficially own in excess of 9.99% of the number of shares of our common stock outstanding immediately after giving effect to its conversion.

Fundamental Transactions. In the event we effect certain mergers, consolidations, sales of substantially all of our assets, tender or exchange offers, reclassifications or share exchanges in which our common stock is effectively converted into or exchanged for other securities, cash or property, we consummate a business combination in which another person acquires 50% of the outstanding shares of our common stock, or any person or group becomes the beneficial owner of 50% of the aggregate ordinary voting power represented by our issued and outstanding common stock, then, upon any subsequent conversion of the Series B convertible preferred stock, the holders of the Series B convertible preferred stock will have the right to receive any shares of the acquiring corporation or other consideration it would have been entitled to receive if it had been a holder of the number of shares of common stock then issuable upon conversion in full of the Series B convertible preferred stock.

Dividends. Holders of Series B convertible preferred stock shall be entitled to receive dividends (on an as-if-converted-to-common-stock basis) in the same form as dividends actually paid on shares of the common stock when, as and if such dividends are paid on shares of common stock.

Voting Rights. Except as otherwise provided in the certificate of designation or as otherwise required by law, the Series B convertible preferred stock has no voting rights.

Liquidation Preference. Upon our liquidation, dissolution or winding-up, whether voluntary or involuntary, holders of Series B convertible preferred stock will be entitled to receive out of our assets, whether capital or surplus, the same amount that a holder of common stock would receive if the Series B convertible preferred stock were fully converted (disregarding for such purpose any conversion limitations under the certificate of designation) to common stock, which amounts shall be paid pari passu with all holders of common stock.

Redemption Rights. We are not obligated to redeem or repurchase any shares of Series B convertible preferred stock. Shares of Series B convertible preferred stock are not otherwise entitled to any redemption rights, or mandatory sinking fund or analogous provisions.

2018 Warrants

The terms and conditions of the warrants included in the 2018 rights offering are as follows:

Exercisability. Each warrant is exercisable at any time and will expire four years from the date of is issuance. The warrants are exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and payment in full for the number of shares of our common stock purchased upon such exercise, except in the case of a cashless exercise as discussed below.

The number of shares of common stock issuable upon exercise of the warrants is subject to adjustment in certain circumstances, including a stock split of, stock dividend on, or a subdivision, combination or recapitalization of the common stock. Upon the merger, consolidation, sale of substantially all of our assets, or other similar transaction, the holders of warrants shall, at the option of the company, be required to exercise the warrants immediately prior to the closing of the transaction, or such warrants shall automatically expire. Upon such exercise, the holders of warrants shall participate on the same basis as the holders of common stock in connection with the transaction.

Cashless Exercise. If at any time there is no effective registration statement registering, or the prospectus contained therein is not available for issuance of, the shares issuable upon exercise of the warrant, the holder may exercise the warrant on a cashless basis. When exercised on a cashless basis, a portion of the warrant is cancelled in payment of the purchase price payable in respect of the number of shares of our common stock purchasable upon such exercise.

Exercise Price. Each warrant represents the right to purchase one share of common stock at an exercise price of $4.048 per share. In addition, the exercise price per share is subject to adjustment for stock dividends, distributions, subdivisions, combinations, or reclassifications, and for certain dilutive issuances. Subject to limited exceptions, a holder of warrants will not have the right to exercise any portion of the warrant to the extent that, after giving effect to the exercise, the holder, together with its affiliates, and any other person acting as a group together with the holder or any of its affiliates, would beneficially own in excess of 4.99% of the number of shares of our common stock outstanding immediately after giving effect to its exercise. The holder, upon notice to the Company, may increase or decrease the beneficial ownership limitation provisions of the warrant, provided that in no event shall the limitation exceed 9.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise of the warrant.

Transferability. Subject to applicable laws and restrictions, a holder may transfer a warrant upon surrender of the warrant to us with a completed and signed assignment in the form attached to the warrant. The transferring holder will be responsible for any tax that liability that may arise as a result of the transfer.

Exchange Listing. We do not intend to apply to list the warrants on any securities exchange or recognized trading system.

Rights as Stockholder. Except as set forth in the warrant, the holder of a warrant, solely in such holder’s capacity as a holder of a warrant, will not be entitled to vote, to receive dividends, or to any of the other rights of our stockholders.

Redemption Rights. We may redeem the warrants for $0.18 per warrant if the volume-weighted-average-price of our common stock equals or exceeds $10.56 per share for ten consecutive trading days, provided that we may not do so prior to the first anniversary of closing of the rights offering.

Outstanding Warrants

As of June 30, 2018, warrants to purchase 4,760,270 shares of common stock were outstanding including:

	Outstanding Warrants to Purchase Shares		Exercise Price		Expiration Date

2014 public offering		6,483		$540.00	January 29, 2019
Placement agent fees for Company’s offerings		1,231		381.60 – 1,044.00	August - November, 2018
2017 Warrant A private placement		441,670		3.78	August 22, 2018
2017 Warrant B private placement		441,670		3.78	December 22, 2018
2018 Warrants		3,869,216		4.05	May 30, 2022
		4,760,270

Conversion of Series B Convertible Preferred Stock

During the three months ended June 30, 2018, certain holders of the Series B convertible preferred stock exercised their conversion option and converted an aggregate of 7,822 shares of Series B convertible preferred stock into 2,222,147 shares of the Company's common stock based on the conversion ratio of approximately 284 shares of common stock for each share of Series B convertible preferred stock.

NOTE 8: NET LOSS PER SHARE

The Company accounts for and discloses net income (loss) per common share in accordance with ASC Topic 260, Earnings Per Share. Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. In addition, in computing the dilutive effect of convertible securities, the numerator is adjusted to add back any convertible preferred dividends. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of potential future exercises of outstanding stock options and common stock warrants. Because the inclusion of potential common shares would be anti-dilutive for all periods presented they have been excluded from the calculation.

The following table summarizes the Company’s calculation of net loss per common share:


	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
Net Loss Per share
Numerator
Net loss	$	(4,142,577	)	$	(2,241,489	)	$	(6,016,959)		$	(3,945,043	)
Deemed dividend attributable to preferred stock		(4,782,100	)		(2,568,132	)		(4,782,100)			(2,568,132	)
Net loss attributable to common shareholders	$	(8,924,677	)	$	(4,809,621	)	$	(10,799,059)		$	(6,513,175	)
Denominator
Weighted average common shares outstanding		3,073,803			623,004			2,864,033			470,139
Basic and diluted net loss per share	$	(2.90	)	$	(7.72	)	$	(3.77	)	$	(13.85	)

The following table sets forth the number of potential common shares excluded from the calculation of net loss per diluted share for the three and six months ended June 30, 2018 and 2017 because including them would be anti-dilutive:

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Options to purchase common stock		200,954		93,464		187,391		62,841
Series A convertible preferred stock				182,030				91,518
Series B convertible preferred stock		900,367				452,671
Warrants to purchase common stock		2,275,808		511,650		1,599,074		273,905
Total		3,377,129		787,144		2,239,136		428,264

For the three and six months ended June 30, 2018 and 2017, the average price of our common stock was less than the exercise price of the vested stock options and exercisable warrants.

NOTE 9: INCOME TAXES

Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.

As a result of the Company’s cumulative losses, management has concluded that a full valuation allowance against the Company’s net deferred tax assets is appropriate. No income tax liabilities existed as of June 30, 2018 and December 31, 2017 due to the Company’s continuing operating losses.

NOTE 10: CONCENTRATION OF CREDIT RISK

Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At June 30, 2018 and December 31, 2017, the Company had $14,986,736 and $6,967,469 in excess of the FDIC insured limit, respectively.

NOTE 11: COMMITMENTS AND CONTINGENCIES

Lease Commitments

The Company has a commitment under an operating lease to pay future minimum lease payments of $4,930, all of which is due in the year ending December 31, 2018.

Litigation and Contingencies

On October 10, 2013, a putative securities class action complaint, captioned Cook v. Atossa Genetics, Inc., et al., No. 2:13-cv-01836-RSM, was filed in the United States District Court for the Western District of Washington against us, certain of our directors and officers and the underwriters of our November 2012 initial public offering. The complaint alleged that all defendants violated Sections 11 and 12(a)(2), and that we and certain of our directors and officers violated Section 15, of the Securities Act by making material false and misleading statements and omissions in the offering’s registration statement, and that we and certain of our directors and officers violated Sections 10(b) and 20A of the Exchange Act and SEC Rule 10b-5 promulgated thereunder by making false and misleading statements and omissions in the registration statement and in certain of our subsequent press releases and SEC filings with respect to our NAF specimen collection process, our ForeCYTE Breast Health Test and our MASCT device. The complaint sought, on behalf of persons who purchased our common stock between November 8, 2012 and October 4, 2013, inclusive, damages of an unspecific amount.

On March 23, 2018, the parties filed a stipulation of settlement with the court to settle the matter for $3.5 million, completely funded by defendants’ insurers, and on July 20, 2018 the Court approved the settlement.

We are subject to other legal proceedings and claims that arise in the normal course of business. We believe these matters are either without merit or of a kind that should not have a material effect, individually or in the aggregate, on our financial position, results of operations or cash flows.

NOTE 12: STOCK BASED COMPENSATION

Stock Option and Incentive Plan

On September 28, 2010, the Board of Directors approved the adoption of the 2010 Stock Option and Incentive Plan the (“2010 Plan”) to provide for the grant of equity-based awards to employees, officers, non-employee directors and other key persons providing services to the Company. Awards of incentive options may be granted under the 2010 Plan until September 2020. No other awards may be granted under the 2010 Plan after the date that is 10 years from the date of stock-holder approval. An aggregate of 5,556 shares were initially reserved for issuance in connection with awards granted under the 2010 Plan and on May 18, 2016, an additional 11,111 shares were reserved for issuance under the 2010 Plan. On May 9, 2017, the stockholders approved an additional 125,000 shares for issuance under the 2010 Plan. On April 12, 2018, the stockholders approved an additional 500,000 shares for issuance under the 2010 Plan.

The following table presents the automatic additions to the 2010 Plan since inception pursuant to the “evergreen” terms of the 2010 Plan:

January 1,	Number of shares
2012		2,502
2013		2,871
2014		4,128
2015		5,463
2016		18,368
2017		12,623
2018		106,076
Total additional shares		152,031

The Company granted 611,668 options to purchase shares of common stock under the 2010 Plan during the six months ended June 30, 2018. No options were exercised during the three or six months ended June 30, 2018. There are 3,118 shares available for grant under the 2010 Plan as of June 30, 2018.

Compensation costs associated with the Company’s stock options are recognized, based on the grant-date fair values of these options, over the requisite service period, or vesting period. Accordingly, the Company recognized stock-based compensation expense of $179,050 and $181,408 for the three months ended June 30, 2018 and 2017, respectively and $394,189 and $336,116 for the six months ended June 30, 2018 and 2017, respectively (excluding the liability options discussed below). The fair value of stock options granted for the six months ended June 30, 2018 and 2017 was calculated using the Black-Scholes option-pricing model applying the following assumptions:

	Period ended June 30,
	2018		2017

Risk free interest rate		2.47% - 2.71%		1.86% - 2.04%
Expected term		5.24- 5.57 years		5.32- 6.36 years

Dividend yield		- %		- %
Expected volatility		108.81% - 126.43%		112.86% - 114.19%

Options issued and outstanding as of June 30, 2018 under the 2010 Plan and their activities during the six months then ended are as follows:

	Number of Underlying Shares			Weighted- Average Exercise Price Per Share		Weighted- Average Contractual Life Remaining in Years		Aggregate Intrinsic Value
Outstanding as of January 1, 2018		172,510		$	49.27			$
Granted		611,668			2.39
Forfeited		(338	)		5.64
Expired
Outstanding as of June 30, 2018		783,840			12.70		9.67	$
Exercisable as of June 30, 2018		82,536			93.84		8.19	$
Vested and expected to vest		783,840			12.70		9.67	$

At June 30, 2018, there were 701,304 unvested options outstanding and the related unrecognized total compensation cost associated with these options was approximately $1,810,227. This expense is expected to be recognized over a weighted-average period of 1.71 years.

Option Grants Classified as Liabilities (“Liability Grants”)

On June 27, 2018, the Company issued option awards to Dr. Steven C. Quay, Chairman of the Board, President and Chief Executive Officer and Kyle Guse, Chief Financial Officer, General Counsel and Secretary. The Company granted Dr. Quay 2,300,000 options and granted Mr. Guse 700,000 options, each exercisable for an equivalent number of shares of Company common stock. The options were granted pursuant to an option award agreement and were granted outside the Company’s 2010 Plan; however, they are subject to the terms and conditions of the 2010 Plan.

The Liability Grants are exercisable for shares of common stock at an exercise price of $2.38 per share, which was the fair market value on the date of grant. The options have an exercise period of ten years from their date of issuance. If at the time the options are exercised the Company cannot deliver shares of common stock to the optionee including, for example, if there are insufficient shares available under the Plan at the time of exercise, then in lieu of the optionee paying the exercise price and the Company issuing shares of stock, the option may only be exercised on a cash “net basis” so that the Company will pay cash in an amount equal to the excess of the fair market value of the common stock over the option exercise price. There currently are not sufficient shares available under the Plan and the Company would be obligated to settle these options in cash if they were exercised. Because these options contain provisions that could require the Company to settle the options in cash in an event outside the Company’s control, they are accounted for as liabilities.

The Liability Grants are subject to vesting requirements. Twenty-five percent of the options have vested as of the grant date, 50% of the options will vest quarterly over two years, and the remaining 25% will vest upon achievement of certain milestones related to clinical trial progress.

Compensation costs associated with the Liability Grants are initially recognized, based on the grant-date fair values of these options, over the requisite or vesting period for time-based options or when it is probable the performance criteria will be achieved for options that vest based on performance. Compensation cost is remeasured each period based on the market value of our underlying stock until award vesting or settlement.

For the three and six months ended June 30, 2018, the Company recognized compensation expense related to these options of $1,557,163.

The fair value of liability options granted for the six months ended June 30, 2018 was calculated using the Black-Scholes option-pricing model applying the following assumptions:

	Six months ended June 30,
	2018

Risk free interest rate		2.71%
Expected term		5.0 years

Dividend yield		- %
Expected volatility		125.0%

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of the financial condition and results of operations should be read in conjunction with the financial statements and the related notes included elsewhere in this report. This discussion contains forward-looking statements, which are based on assumptions about the future of the Company’s business. The actual results could differ materially from those contained in the forward-looking statements. Please read “Forward-Looking Statements” included below for additional information regarding forward-looking statements.

Forward-Looking Statements

This report contains, in addition to historical information, certain information, assumptions and discussions that may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We have made these statements in reliance on the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are subject to certain risks and uncertainties, which could cause actual results to differ materially from those projected or anticipated. Although we believe our assumptions underlying our forward-looking statements are reasonable as of the date of this report, we cannot assure you that the forward-looking statements set out in this report will prove to be accurate. We typically identify these forward-looking statements by the use of forward-looking words such as “expect,” “potential,” “continue,” “may,” “will,” “should,” “could,” “would,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or the negative version of those words or other comparable words. Forward-looking statements contained in this report include, but are not limited to, statements about:

	●	whether we can obtain approval from the U.S. Food and Drug Administration (“FDA”) and foreign regulatory bodies, to sell, market and distribute our therapeutics and devices under development;

	●	our ability to successfully complete clinical trials of our pharmaceutical candidates under development, including endoxifen and our intraductal microcatheters to administer therapeutics, including our study using fulvestrant;

	●	the success, cost and timing of our product and drug development activities and clinical trials, including whether the ongoing clinical study using our intraductal microcatheters to administer fulvestrant and other studies will enroll a sufficient number of subjects or be completed in a timely fashion or at all;

	●	our ability to contract with third-party suppliers, manufacturers and service providers, including clinical research organizations, and their ability to perform adequately;

	●	our ability to successfully develop and commercialize new therapeutics currently in development or that we might identify in the future and in the time frames currently expected;

	●	our ability to establish and maintain intellectual property rights covering our products;

	●	our expectations regarding, and our ability to satisfy, federal, state and foreign regulatory requirements;

	●	the accuracy of our estimates of the size and characteristics of the markets that our products and services may address;

●

our expectations as to future financial performance, expense levels and capital sources;

	●	whether the final study results will vary from preliminary study results that we may announce; and

●

our ability to attract and retain key personnel.

These and other forward-looking statements made in this report are presented as of the date on which the statements are made. We have included important factors in the cautionary statements included in this report, particularly in the section titled “ITEM 1A. RISK FACTORS,” that we believe could cause actual results or events to differ materially from the anticipated results as set forth in the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any new information, future events or circumstances that may affect our business after the date of this report. Except as required by law, we do not intend to update any forward-looking statements after the date on which the statement is made, whether as a result of new information, future events or circumstances or otherwise.

Company Overview

We are a clinical-stage pharmaceutical company focused on developing novel, proprietary therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. We are developing Endoxifen with two routes of delivery: a topical formulation, applied like a lotion, for the treatment of a condition called mammographic breast density (or, MBD) and a breast disorder in men called gynecomastia; and an oral formulation to treat stage 1 or 2 breast cancer in the “window of opportunity” between diagnosis and surgery and for breast cancer survivors who do not benefit from taking oral tamoxifen, a current FDA-approved standard of care. We are also developing our patented intraductal microcatheter technology to potentially target the delivery of therapies, including fulvestrant, immunotherapies and Chimeric Antigen Receptor T-cell therapies (CAR-T therapies), directly to the site of breast cancer.

In 2017, we completed a Phase 1 clinical study of our proprietary oral and topical formulations of Endoxifen. All objectives were met: there were no clinically significant safety signals and no clinically significant adverse events, and both the oral and topical Endoxifen were well tolerated. In the topical arm of the study, low but measurable Endoxifen levels were detected in the blood in a dose-dependent fashion. In the oral arm of the study, participants exhibited dose-dependent Endoxifen levels that met or exceeded the published therapeutic level. The median time for patients in the study to reach the steady-state serum levels of Endoxifen while taking daily doses of oral Endoxifen was 7 days. Published literature indicates that it takes approximately 50-200 days for patients to reach steady-state Endoxifen levels when taking daily doses of oral tamoxifen.

We are currently conducting a Phase 2 study at Montefiore Medical Center, Bronx, New York, using our intraductal microcatheter technology to deliver fulvestrant. Our program to use our intraductal microcatheters to deliver CAR-T and other immunotherapies is in the research and development phase.

In March 2018, we expanded our breast health program by launching a mens’ breast health initiative with a Phase 1 study of our topical Endoxifen in men. The objectives of the placebo-controlled, repeat dose study of 24 healthy male volunteers are to assess the pharmacokinetics of proprietary topical Endoxifen dosage forms over 28 days, as well as to assess safety and tolerability. Depending on the results of this study, we plan to develop our topical Endoxifen for gynecomastia.

We have opened enrollment in two Phase 2 studies of our proprietary Endoxifen: one in Stockholm, Sweden using our topical Endoxifen to treat MBD and another in Australia using our oral Endoxifen to treat patients in the window of opportunity between diagnosis and surgery.

Our key objectives are to advance our programs through Phase 2 trials and then evaluate further development independently or with partners.

Research and Development Phase

We are in the research and development phase and are not currently marketing any products or services. We do not anticipate generating revenue unless and until we develop and launch our pharmaceutical programs.

Critical Accounting Policies and Estimates

In our Annual Report on Form 10-K for the year ended December 31, 2017, we disclosed our critical accounting policies and estimates upon which our financial statements are derived. There have been no changes to these policies since December 31, 2017. Readers are encouraged to review these disclosures in conjunction with the review of this report.

Results of Operations

Three and Six Months Ended June 30, 2018 and 2017

Revenue and Cost of Revenue:

For the three and six months ended June 30, 2018 and 2017, we had no revenue and no associated cost of revenue.

Operating Expenses: Total operating expenses were approximately $4.1 million and $6.0 million for the three and six months ended June 30, 2018, respectively, consisting of general and administrative (G&A) expenses of approximately $2.7 million and $4.1 million, respectively, and research and development (R&D) expenses of approximately $1.5 million and $1.9 million, respectively. Total operating expenses were approximately $1.9 million and $3.6 million for the three and six months ended June 30, 2017, respectively, consisting of G&A expense of approximately $1.1 million and $2.2 million, respectively, and R&D expenses of $0.8 million and $1.4 million, respectively.

Total operating expenses for the three and six months ended June 30, 2018 as compared to the same periods of 2017 increased approximately $2.3 million, or 118.46%, and increased $2.4 million, or 67.15%, respectively.

General and Administrative Expenses: G&A expenses for the three months ended June 30, 2018 were approximately $2,675,000, an increase of $1,603,000 or 149.49%, from approximately $1,072,000, for the same period in 2017. G&A expenses for the six months ended June 30, 2018 were approximately $4,078,000, an increase of $1,847,000 or 82.77%, from approximately $2,232,000 for the same period in 2017. G&A expenses consist primarily of personnel and related benefit costs, facilities, professional services, insurance, and public company related expenses. The increase in G&A expenses is mainly attributed to an increase in stock-based compensation expense of $1.0 million, payroll expenses resulting from retroactive salary increases and one-time bonus payments of $350,000.

Research and Development Expenses: R&D expenses for the three months ended June 30, 2018 were approximately $1,468,000, an increase of $644,000 or 78.10%, from approximately $824,000, for the same period in 2017. R&D expenses for the six months ended June 30, 2018 were approximately $1,939,000, an increase of $570,000 or 41.68%, from approximately $1,368,000 for the same period in 2017. The increase in R&D expenses is mainly attributable to an increase in stock-based compensation expense of $0.6 million. R&D expenses primarily consist of salaries, manufacturing and clinical trial expenses associated with our Endoxifen program. We expect our R&D expenses to increase throughout 2018 as we continue to advance our phase 2 Endoxifen clinical trials and continue the development other indications and pharmaceuticals.

Warrant Financing Costs and Change in Fair Value of Common Stock Warrants: The April 2017 financing included the issuance of common stock liability warrants. The Company incurred financing costs associated with these common stock liability warrants of $192,817 upon issuance. The Company also recorded changes in the fair value of the liability warrants during the three months and six months ended June 30, 2017 of $152,447. There were no common stock liability warrants issued during the three and six months ended June 30, 2018.

Liquidity and Capital Resources

We have a history of operating losses as we have focused our efforts on raising capital and building our products and services in our pipeline. The Company’s consolidated financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses and negative operating cash flows since inception. For the six months ended June 30, 2018, the Company recorded a net loss of approximately $6.0 million, and used approximately $4.2 million of cash in operating activities. As of June 30, 2018, the Company had approximately $15.2 million in cash and cash equivalents and working capital of approximately $13.4 million. The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs and allow it to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. The Company can give no assurances that any additional capital that it is able to obtain, if any, will be sufficient to meet its needs, or that any such financing will be obtainable on acceptable terms. If the Company is unable to obtain adequate capital, it could be forced to cease operations or substantially curtail is commercial activities. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities should the Company be unable to continue as a going concern.

As of the date of filing this quarterly report, we expect that our existing resources will be sufficient to fund our planned operations for the next 12 to 18 months; however, additional capital resources will be needed to fund operations longer-term.

Additional funding may not be available to us on acceptable terms or at all. In addition, the terms of any financing may adversely affect the holdings or the rights of our stockholders. For example, if we raise additional funds by issuing equity securities or by selling debt securities, if convertible, further dilution to our existing stockholders would result. To the extent our capital resources are insufficient to meet our future capital requirements, we will need to finance our future cash needs through public or private equity offerings, collaboration agreements, debt financings or licensing arrangements.

If adequate funds are not available, we may be required to terminate, significantly modify or delay our development programs, reduce our planned commercialization efforts, or obtain funds through collaborators that may require us to relinquish rights to our technologies or product candidates that we might otherwise seek to develop or commercialize independently. Further, we may elect to raise additional funds even before we need them if we believe the conditions for raising capital are favorable.

Cash Flows

As of June 30, 2018, the Company had cash and cash equivalents and restricted cash of $15.3 million.

Net Cash Flows from Operating Activities: Net cash used in operating activities was approximately $4.2 million for the six months ended June 30, 2018, compared with approximately $3.2 million for the six months ended June 30, 2017. The increase in the 2018 period as compared to 2017 results primarily from an increase in compensation, increased consulting fees, and increased patent expenses in 2018.

Net Cash Flows from Investing Activities: Net cash used in investing activities was approximately $51,500 for the six months ended June 30, 2018, compared with no cash used for the six months ended June 30, 2017. The increase in 2018 was attributable to the purchases of fixed asset equipment in 2018 for R&D activities.

Net Cash Flows from Financing Activities: Net cash provided by financing activities generated proceeds of $12.3 million for the six months ended June 30, 2018, as compared with $3.9 million for the six months ended June 30, 2017. The increase is mainly attributed to our larger completed rights offering in the second quarter of 2018 as compared to the same period in 2017.

Off-Balance Sheet Arrangements

We do not currently have, nor have we ever had, any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we do not engage in trading activities involving non-exchange traded contracts.

Recent Accounting Pronouncements

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows, amending the presentation of restricted cash within the statement of cash flows. The new guidance requires that restricted cash be included within cash and cash equivalents on the statement of cash flows. The Company adopted the provisions of ASU No. 2016-18 as of January 1, 2018 and has included restricted cash within cash and cash equivalents in the statements of cash flows. For the three and six months ended June 30, 2018 and June 30, 2017, we included $55,000 of restricted cash in cash and cash equivalents on the statement of cash flows. The restricted cash represents a required deposit for the Company credit card and is restricted until the Company no longer has the credit card or the limit changes on the credit card.

In July 2017, the FASB issued ASU 2017-11, Accounting for Certain Financial Instruments with Down Round Features and Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Part I of this ASU addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of future equity offerings. Current accounting guidance requires financial instruments with down round features to be accounted for at fair value. Part II of the Update applies only to nonpublic companies and is therefore not applicable to the Company. The amendments in Part I of the Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. This Update is effective for public entities for fiscal years beginning after December 15, 2018. Early adoption is permitted. The Company early adopted the provisions of ASU No. 2017-11 as of January 1, 2018. As the Company does not have any financial instruments with down round features outstanding as of June 30, 2018, this ASU and it did not have a material impact on the financial statements upon adoption.

In June 2018, The FASB issued ASU 2018-07, Compensation-Stock Compensation Improvements to Nonemployee Share Based Payment Accounting. This ASU simplifies several aspects of the accounting for non-employee share-based payment transactions resulting from expanding the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide financing to the issuer or was granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with customers. This update is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoptions is permitted. The Company early adopted the provisions of ASU No. 2018-07 as of April 1, 2018 and it did not have a material impact on the financial statements upon adoption.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES.

Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2018. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our principal executive officer and principal financial officer concluded that, as of June 30, 2018, the Company’s disclosure controls and procedures were effective at the reasonable assurance level.

No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the quarter ended June 30, 2018 that has materially affected, or is reasonably likely to materially affect our disclosure controls and procedures.

PART II OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Litigation and Contingencies

ITEM 1A. RISK FACTORS

There have been no material changes to the risk factors described in our Annual Report on Form 10-K, as filed with the SEC on March 8, 2018.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Not applicable.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

Not applicable.

ITEM 6. EXHIBITS

(a)

Exhibits

				Incorporated by Reference Herein
Exhibit No.		Description		Form		Date


1.1	Form of Dealer-Manager Agreement	Amendment No. 1 to Registration Statement on Form S-1, as Exhibit 1.1	April 23, 2018

3.3	Certificate of Amendment to Amended and Restated Certificate of Incorporation of Atossa Genetics Inc.	Current Report on Form 8-K, as Exhibit 4.1	April 23, 2018

4.1	Form of Certificate of Designation of Preference, Rights and Limitations of Series B Convertible Preferred Stock	Current Report on Form 8-K as Exhibit 3.1	May 30, 2018

4.2	Form of Warrant Agreement	Current Report on Form 8-K as Exhibit 4.1	May 30, 2018

4.3	Form of Warrant Certificate	Amendment No. 1 to Registration Statement on Form S-1, as Exhibit 4.3	April 23, 2018

4.4	Form of Non-Transferable Subscription Rights Certificate	Amendment No. 1 to Registration Statement on Form S-1, as Exhibit 4.4	April 23, 2018

31.1	Certification pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 of Steven C. Quay	Filed herewith

31.2	Certification pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 of Kyle Guse	Filed herewith

32.1	Certification pursuant to 18 U.S.C. Section 1350 of Steven C. Quay	Filed herewith

32.2	Certification pursuant to 18 U.S.C. Section 1350 of Kyle Guse	Filed herewith

99.3	Form of Letter to Brokers, Dealers, Banks and Other Nominees	Amendment No.2 to Registration Statement on Form S-1, as Exhibit 99.3	May 3, 2018

99.4	Form of Broker Letter to Clients Who Are Beneficial Holders	Amendment No.2 to Registration Statement on Form S-1, as Exhibit 99.4	May 3, 2018

99.5	Form of Beneficial Owner Election Form	Amendment No. 1 to Registration Statement on Form S-1, as Exhibit 99.5	April 23, 2018

99.6	Form of Nominee Holder Certification	Amendment No. 1 to Registration Statement on Form S-1, as Exhibit 99.6	April 23, 2018

99.7	Form of Notice of Important Tax Information	Amendment No. 1 to Registration Statement on Form S-1, as Exhibit 99.7	April 23, 2018


101		Interactive Data Files pursuant to Rule 405 of Regulation S-T		Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: August 13, 2018

/s/ Steven C. Quay
President and Chief Executive Officer
(On behalf of the Registrant)

/s/ Kyle Guse
Kyle Guse
Chief Financial Officer, General Counsel and Secretary
(As Principal Financial and Accounting Officer)

EX-31.1 2 s111760_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO RULE 13a-14(a)

OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Steven C. Quay, certify that:

1. I have reviewed this Quarterly Report of Atossa Genetics Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	Date: August 13, 2018

	/s/ Steven C. Quay
	Steven C. Quay
	Chief Executive Officer and President
	(Principal executive officer)

EX-31.2 3 s111760_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO RULE 13a-14(a)

OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Kyle Guse, certify that:

1. I have reviewed this Quarterly Report of Atossa Genetics Inc.;

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	Date: August 13, 2018

	/s/Kyle Guse
	Kyle Guse
	Chief Financial Officer, General Counsel and Secretary
	(Principal financial and accounting officer)

EX-32.1 4 s111760_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Atossa Genetics Inc. (the “Company”) on Form 10-Q for the period ending June 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Steven C. Quay, Chief Executive Officer and President of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	Date: Aug 13, 2018

	/s/ Steven C. Quay
	Steven C. Quay
	Chief Executive Officer and President
	(Principal executive officer)

EX-32.2 5 s111760_ex32-2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Atossa Genetics Inc. (the “Company”) on Form 10-Q for the period ending June 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Kyle Guse, Chief Financial Officer, General Counsel and Secretary of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	Date: Aug 13, 2018

	/s/ Kyle Guse
	Kyle Guse
	Chief Financial Officer, General Counsel and Secretary
	(Principal financial and accounting officer)

EX-101.INS 6 atos-20180630.xml XBRL INSTANCE FILE 0001488039 2018-08-10 0001488039 2018-01-01 2018-06-30 0001488039 2018-06-30 0001488039 2017-12-31 0001488039 2017-01-01 2017-06-30 0001488039 2018-04-01 2018-06-30 0001488039 2017-04-01 2017-06-30 0001488039 2016-12-31 0001488039 us-gaap:SeriesAPreferredStockMember 2018-06-30 0001488039 us-gaap:SeriesBPreferredStockMember 2018-06-30 0001488039 us-gaap:SeriesAPreferredStockMember 2017-12-31 0001488039 us-gaap:SeriesBPreferredStockMember 2017-12-31 0001488039 atos:ReverseStockSplitMember us-gaap:SubsequentEventMember 2018-08-19 2018-08-20 0001488039 us-gaap:SubsidiariesMember 2018-01-01 2018-06-30 0001488039 us-gaap:SubsidiariesMember 2017-01-01 2017-12-31 0001488039 atos:TwoThousandAndFourteenPublicOfferingMember 2018-01-01 2018-06-30 0001488039 atos:PlacementAgentFeeMember us-gaap:MinimumMember 2018-01-01 2018-06-30 0001488039 atos:PlacementAgentFeeMember us-gaap:MaximumMember 2018-01-01 2018-06-30 0001488039 atos:TwoThousandAndSeventeenWarrantAPrivatePlacementMember 2018-01-01 2018-06-30 0001488039 atos:TwoThousandAndSeventeenWarrantBPrivatePlacementMember 2018-01-01 2018-06-30 0001488039 atos:TwoThousandAndEighteenWarrantsMember 2018-01-01 2018-06-30 0001488039 atos:TwoThousandAndFourteenPublicOfferingMember 2018-06-30 0001488039 atos:PlacementAgentFeeMember 2018-06-30 0001488039 atos:PlacementAgentFeeMember us-gaap:MinimumMember 2018-06-30 0001488039 atos:PlacementAgentFeeMember us-gaap:MaximumMember 2018-06-30 0001488039 atos:TwoThousandAndSeventeenWarrantAPrivatePlacementMember 2018-06-30 0001488039 atos:TwoThousandAndSeventeenWarrantBPrivatePlacementMember 2018-06-30 0001488039 atos:TwoThousandAndEighteenWarrantMember 2018-06-30 0001488039 us-gaap:StockOptionMember 2018-04-01 2018-06-30 0001488039 us-gaap:SeriesBPreferredStockMember 2018-04-01 2018-06-30 0001488039 us-gaap:WarrantMember 2018-04-01 2018-06-30 0001488039 us-gaap:StockOptionMember 2017-04-01 2017-06-30 0001488039 us-gaap:SeriesAPreferredStockMember 2017-04-01 2017-06-30 0001488039 us-gaap:WarrantMember 2017-04-01 2017-06-30 0001488039 2017-04-01 2017-06-23 0001488039 us-gaap:StockOptionMember 2018-01-01 2018-06-30 0001488039 us-gaap:SeriesBPreferredStockMember 2018-01-01 2018-06-30 0001488039 us-gaap:WarrantMember 2018-01-01 2018-06-30 0001488039 us-gaap:StockOptionMember 2017-01-01 2017-06-30 0001488039 us-gaap:SeriesAPreferredStockMember 2017-01-01 2017-06-30 0001488039 us-gaap:WarrantMember 2017-01-01 2017-06-30 0001488039 2018-03-22 2018-03-23 0001488039 atos:Plan2012Member 2018-01-01 2018-06-30 0001488039 atos:Plan2013Member 2018-01-01 2018-06-30 0001488039 atos:Plan2014Member 2018-01-01 2018-06-30 0001488039 atos:Plan2015Member 2018-01-01 2018-06-30 0001488039 atos:Plan2016Member 2018-01-01 2018-06-30 0001488039 atos:Plan2017Member 2018-01-01 2018-06-30 0001488039 atos:Plan2018Member 2018-01-01 2018-06-30 0001488039 us-gaap:MinimumMember 2018-01-01 2018-06-30 0001488039 us-gaap:MaximumMember 2018-01-01 2018-06-30 0001488039 us-gaap:MinimumMember 2017-01-01 2017-06-30 0001488039 us-gaap:MaximumMember 2017-01-01 2017-06-30 0001488039 2017-06-30 0001488039 atos:SubscriptionRightsMember 2018-05-09 0001488039 atos:SubscriptionRightsMember 2018-05-08 2018-05-09 0001488039 atos:SubscriptionRightsMember us-gaap:SeriesBPreferredStockMember 2018-05-08 2018-05-09 0001488039 atos:SubscriptionRightsMember us-gaap:WarrantMember us-gaap:CommonStockMember 2018-05-08 2018-05-09 0001488039 us-gaap:SeriesBPreferredStockMember 2018-05-29 0001488039 atos:SubscriptionRightsMember 2018-05-27 2018-05-30 0001488039 atos:SubscriptionRightsMember us-gaap:SeriesBPreferredStockMember 2018-05-27 2018-05-30 0001488039 atos:SubscriptionRightsMember us-gaap:WarrantMember us-gaap:CommonStockMember 2018-05-30 0001488039 atos:SubscriptionRightsMember us-gaap:WarrantMember us-gaap:CommonStockMember 2018-05-27 2018-05-30 0001488039 atos:SubscriptionRightsMember us-gaap:SeriesBPreferredStockMember 2018-01-01 2018-06-30 0001488039 atos:SubscriptionRightsMember us-gaap:WarrantMember us-gaap:CommonStockMember 2018-01-01 2018-06-30 0001488039 us-gaap:SeriesBPreferredStockMember 2018-01-01 2018-06-30 0001488039 atos:Plan2010Member us-gaap:BoardOfDirectorsChairmanMember 2018-06-26 2018-06-27 0001488039 atos:Plan2010Member us-gaap:ChiefFinancialOfficerMember 2018-06-26 2018-06-27 0001488039 atos:Plan2010Member 2018-04-01 2018-06-30 0001488039 us-gaap:PreferredStockMember 2018-01-01 2018-06-30 0001488039 us-gaap:PreferredStockMember 2018-06-30 0001488039 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-06-30 0001488039 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001488039 us-gaap:CommonStockMember 2018-01-01 2018-06-30 0001488039 us-gaap:CommonStockMember 2017-12-31 0001488039 us-gaap:CommonStockMember 2018-06-30 0001488039 atos:AdditionalPaidInCapital1Member 2018-01-01 2018-06-30 0001488039 atos:AdditionalPaidInCapital1Member 2017-12-31 0001488039 atos:AdditionalPaidInCapital1Member 2018-06-30 0001488039 us-gaap:RetainedEarningsMember 2018-01-01 2018-06-30 0001488039 us-gaap:RetainedEarningsMember 2017-12-31 0001488039 us-gaap:RetainedEarningsMember 2018-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure ATOSSA GENETICS INC 0001488039 10-Q ATOS 2018-06-30 false --12-31 No No Yes Smaller Reporting Company Q2 2018 5069599

16577846

8164094

13566765

6938687

5234116

477342

877329

71887674

78898602

-65426329

-71443288

-65426329

78898602

71887674

3011081

1225407

23331

15534

952657

784867

286713

90105

191217

334901

16577846

8164094

48867

178907

59882

75686

60926

11467

16408171

7898034

50035

16344

626011

358277

440389

250944

55000

15236736

7217469

-6016959

-3945043

-4142577

-2241489

-6016959

1938712

1368396

1467736

824094

616000

-4219793

-3209575

7797

13074

196608

27053

167790

-287479

-143684

241491

-56644

-25831

267734 626000 268000

189445

56769

-17695

394189

336115

-51491

51491

15291736

7272469

3082962

3745023

8019267

662061

39703

39705

NOTE 1: NATURE OF OPERATIONS   Atossa Genetics Inc. (the “Company”) was incorporated on April 30, 2009 in the State of Delaware. The Company was formed to develop and market medical devices, laboratory tests and therapeutics to address breast health conditions. The Company’s fiscal year ends on December 31. The Company is focused on development of its pharmaceutical and drug delivery programs.

NOTE 2: GOING CONCERN   The Company’s consolidated financial statements are prepared using Generally Accepted Accounting Principles in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses and negative operating cash flows since inception. For the six months ended June 30, 2018, the Company recorded a net loss of approximately $6.0 million and used approximately $4.2 million of cash in operating activities. As of June 30, 2018 the Company had approximately $15.2 million in cash and cash equivalents and working capital of approximately $13.4 million. The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs and allow it to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. The Company can give no assurances that any additional capital that it is able to obtain, if any, will be sufficient to meet its needs, or that any such capital will be obtained on acceptable terms. If the Company is unable to obtain adequate capital, it could be forced to cease operations or substantially curtail its activities. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities should the Company be unable to continue as a going concern.   Management’s plan to continue as a going concern includes obtaining additional capital resources. Management’s plans to obtain such resources for the Company include obtaining capital from the sale of its equity securities, potential exercise of outstanding warrants, and short-term borrowings from banks, stockholders or other related parties, if needed. However, management cannot provide any assurance that the Company will be successful in accomplishing any of its plans.   As of the date of filing this report, we expect that our existing resources will be sufficient to fund our planned operations for the next 12 to 18 months; however, additional capital resources will be needed to fund operations longer-term.   The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraphs and eventually to secure other sources of financing and attain profitable operations.

NOTE 4: PREPAID EXPENSES   Prepaid expenses consisted of the following:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center">June 30, 2018</td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center">December 31, 2017</td> <td style="font-weight: bold; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Prepaid insurance</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right">148,284</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right">125,056</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Retainer and security deposits</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">16,718</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">14,218</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Professional services</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">110,094</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">97,788</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Prepaid research and development</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">115,014</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Financial exchange fees</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">27,500</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Other</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">22,779</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">13,882</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Total prepaid expenses</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">440,389</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">250,944</td></tr> </table> NOTE 5: RESEARCH AND DEVELOPMENT TAX REBATE RECEIVABLE   On May 23, 2017 Atossa formed a wholly-owned subsidiary in Australia called Atossa Genetics AUS Pty Ltd. The purpose of this subsidiary is to perform research and development activities (“R&D”) including our Phase 1 and Phase 2 endoxifen clinical trials. Australia offers an R&D cash rebate of $0.435 per dollar spent on qualified R&D activities incurred in the country. For the six months ended June 30, 2018, the Company incurred qualified R&D expenses of approximately $616,000, resulting in an increase to the R&D rebate receivable of approximately $268,000 from the year ended December 31, 2017 balance, and a corresponding offset to R&D expenses in the same amount. At June 30, 2018, we had a total R&D rebate receivable of approximately $626,000.

NOTE 6: PAYROLL LIABILITIES   Payroll liabilities consisted of the following:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center">June 30, 2018</td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center">December 31, 2017</td> <td style="font-weight: bold; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Accrued bonus payable</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right">662,512</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right">566,000</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Accrued vacation</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">167,174</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">147,861</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Accrued payroll liabilities</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">122,971</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">71,006</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: left">Total payroll liabilities</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">952,657</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">784,867</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

NOTE 7: STOCKHOLDERS’ EQUITY   The Company is authorized to issue a total of 185,000,000 shares of stock consisting of 175,000,000 shares of common stock, par value $0.18 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share. The Company has designated 750,000 shares of Series A junior participating preferred stock, par value $0.001 per share, 4,000 shares of Series A convertible preferred stock, par value $0.001 per share, and 25,000 shares of Series B convertible preferred stock through the filings of certificates of designation with the Delaware Secretary of State. No shares of Series A junior participating preferred stock and no shares of Series A convertible preferred stock are issued and outstanding as of June 30, 2018.   On May 19, 2014, the Company adopted a stockholder rights agreement which provides that all stockholders of record on May 26, 2014 received a non-taxable distribution of one preferred stock purchase right for each share of the Company’s common stock held by such stockholder. Each right is attached to and trades with the associated share of common stock. The rights will become exercisable only if one of the following occurs: (1) a person becomes an “Acquiring Person” by acquiring beneficial ownership of 15% or more of the Company’s common stock (or, in the case of a person who beneficially owned 15% or more of the Company’s common stock on the date the stockholder rights agreement was executed, by acquiring beneficial ownership of additional shares representing 2.0% of the Company’s common stock then outstanding (excluding compensatory arrangements)), or (2) a person commences a tender offer that, if consummated, would result in such person becoming an Acquiring Person. If a person becomes an Acquiring Person, each right will entitle the holder, other than the Acquiring Person and certain related parties, to purchase a number of shares of the Company’s common stock with a market value that equals twice the exercise price of the right. The initial exercise price of each right is $15.00, so each holder (other than the Acquiring Person and certain related parties) exercising a right would be entitled to receive $30.00 worth of the Company’s common stock. If the Company is acquired in a merger or similar business combination transaction at any time after a person has become an Acquiring Person, each holder of a right (other than the Acquiring Person and certain related parties) will be entitled to purchase a similar amount of stock of the acquiring entity.   2018 Subscription Rights Offering of Units Consisting of Series B Convertible Preferred Stock and Warrants   On May 9, 2018, the Company’s Registration Statement on Form S-1 with the Securities and Exchange Commission was declared effective to offer subscription rights to purchase up to 25,000 units at $1,000 per unit with each unit consisting of one share of Series B convertible preferred stock and warrants to purchase 284 shares of common stock.   On May 29, 2018, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series B convertible preferred stock with the Delaware Secretary of State creating a new series of its authorized preferred stock, par value $0.001 per share, designated as the Series B convertible preferred stock. The number of shares initially constituting the Series B preferred stock was set at 25,000 shares.   On May 30, 2018, the Company completed its previously announced rights offering pursuant to which the Company sold an aggregate of 13,624 units consisting of an aggregate of 13,624 shares of Series B convertible preferred stock and 3,869,216 warrants, with each warrant exercisable for one share of common stock at an exercise price of $4.048 per share (the “2018 Warrants”), resulting in net proceeds to the Company of approximately $12.3 million, after deducting expenses relating to the rights offering, including dealer-manager fees and expenses, and excluding any proceeds received upon exercise of any warrants.   Series B Convertible Preferred Stock.   The terms and provisions of our Series B convertible preferred stock are:   Conversion. Each share of Series B convertible preferred stock is convertible at our option at any time on or after the first anniversary of the closing of the rights offering or at the option of the holder at any time, into the number of shares of our common stock determined by dividing the $1,000 stated value per share of the Series B convertible preferred stock by a conversion price of $3.52 per share. In addition, the conversion price per share is subject to adjustment for stock dividends, distributions, subdivisions, combinations or reclassifications. Subject to limited exceptions, a holder of the Series B convertible preferred stock will not have the right to convert any portion of the Series B convertible preferred stock to the extent that, after giving effect to the conversion, the holder, together with its affiliates, would beneficially own in excess of 9.99% of the number of shares of our common stock outstanding immediately after giving effect to its conversion.   Fundamental Transactions. In the event we effect certain mergers, consolidations, sales of substantially all of our assets, tender or exchange offers, reclassifications or share exchanges in which our common stock is effectively converted into or exchanged for other securities, cash or property, we consummate a business combination in which another person acquires 50% of the outstanding shares of our common stock, or any person or group becomes the beneficial owner of 50% of the aggregate ordinary voting power represented by our issued and outstanding common stock, then, upon any subsequent conversion of the Series B convertible preferred stock, the holders of the Series B convertible preferred stock will have the right to receive any shares of the acquiring corporation or other consideration it would have been entitled to receive if it had been a holder of the number of shares of common stock then issuable upon conversion in full of the Series B convertible preferred stock.   Dividends. Holders of Series B convertible preferred stock shall be entitled to receive dividends (on an as-if-converted-to-common-stock basis) in the same form as dividends actually paid on shares of the common stock when, as and if such dividends are paid on shares of common stock.   Voting Rights. Except as otherwise provided in the certificate of designation or as otherwise required by law, the Series B convertible preferred stock has no voting rights.   Liquidation Preference. Upon our liquidation, dissolution or winding-up, whether voluntary or involuntary, holders of Series B convertible preferred stock will be entitled to receive out of our assets, whether capital or surplus, the same amount that a holder of common stock would receive if the Series B convertible preferred stock were fully converted (disregarding for such purpose any conversion limitations under the certificate of designation) to common stock, which amounts shall be paid pari passu with all holders of common stock.   Redemption Rights. We are not obligated to redeem or repurchase any shares of Series B convertible preferred stock. Shares of Series B convertible preferred stock are not otherwise entitled to any redemption rights, or mandatory sinking fund or analogous provisions.   2018 Warrants    The terms and conditions of the warrants included in the 2018 rights offering are as follows:   Exercisability. Each warrant is exercisable at any time and will expire four years from the date of is issuance. The warrants are exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and payment in full for the number of shares of our common stock purchased upon such exercise, except in the case of a cashless exercise as discussed below.   The number of shares of common stock issuable upon exercise of the warrants is subject to adjustment in certain circumstances, including a stock split of, stock dividend on, or a subdivision, combination or recapitalization of the common stock. Upon the merger, consolidation, sale of substantially all of our assets, or other similar transaction, the holders of warrants shall, at the option of the company, be required to exercise the warrants immediately prior to the closing of the transaction, or such warrants shall automatically expire. Upon such exercise, the holders of warrants shall participate on the same basis as the holders of common stock in connection with the transaction.   Cashless Exercise. If at any time there is no effective registration statement registering, or the prospectus contained therein is not available for issuance of, the shares issuable upon exercise of the warrant, the holder may exercise the warrant on a cashless basis. When exercised on a cashless basis, a portion of the warrant is cancelled in payment of the purchase price payable in respect of the number of shares of our common stock purchasable upon such exercise.   Exercise Price. Each warrant represents the right to purchase one share of common stock at an exercise price of $4.048 per share. In addition, the exercise price per share is subject to adjustment for stock dividends, distributions, subdivisions, combinations, or reclassifications, and for certain dilutive issuances. Subject to limited exceptions, a holder of warrants will not have the right to exercise any portion of the warrant to the extent that, after giving effect to the exercise, the holder, together with its affiliates, and any other person acting as a group together with the holder or any of its affiliates, would beneficially own in excess of 4.99% of the number of shares of our common stock outstanding immediately after giving effect to its exercise. The holder, upon notice to the Company, may increase or decrease the beneficial ownership limitation provisions of the warrant, provided that in no event shall the limitation exceed 9.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise of the warrant.   Transferability. Subject to applicable laws and restrictions, a holder may transfer a warrant upon surrender of the warrant to us with a completed and signed assignment in the form attached to the warrant. The transferring holder will be responsible for any tax that liability that may arise as a result of the transfer.   Exchange Listing. We do not intend to apply to list the warrants on any securities exchange or recognized trading system.   Rights as Stockholder. Except as set forth in the warrant, the holder of a warrant, solely in such holder’s capacity as a holder of a warrant, will not be entitled to vote, to receive dividends, or to any of the other rights of our stockholders.   Redemption Rights. We may redeem the warrants for $0.18 per warrant if the volume-weighted-average-price of our common stock equals or exceeds $10.56 per share for ten consecutive trading days, provided that we may not do so prior to the first anniversary of closing of the rights offering.   Outstanding Warrants   As of June 30, 2018, warrants to purchase 4,760,270 shares of common stock were outstanding including:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Outstanding Warrants to Purchase Shares</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Expiration Date</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>2014 public offering</td> <td> </td> <td> </td> <td style="text-align: right">6,483</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">$540.00</td> <td> </td> <td> </td> <td style="text-align: right">January 29, 2019</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Placement agent fees for Company’s offerings</td> <td> </td> <td> </td> <td style="text-align: right">1,231</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">381.60 – 1,044.00</td> <td> </td> <td> </td> <td style="text-align: right">August - November, 2018</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>2017 Warrant A private placement</td> <td> </td> <td> </td> <td style="text-align: right">441,670</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3.78</td> <td> </td> <td> </td> <td style="text-align: right">August 22, 2018</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">2017 Warrant B private placement</td> <td style="padding-bottom: 1pt"> </td> <td> </td> <td style="text-align: right">441,670</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: right">3.78</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: right">December 22, 2018</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">2018 Warrants</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3,869,216</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: right">4.05</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: right">May 30, 2022</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">4,760,270</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td></tr> </table>   Conversion of Series B Convertible Preferred Stock   During the three months ended June 30, 2018, certain holders of the Series B convertible preferred stock exercised their conversion option and converted an aggregate of 7,822 shares of Series B convertible preferred stock into 2,222,147 shares of the Company's common stock based on the conversion ratio of approximately 284 shares of common stock for each share of Series B convertible preferred stock.

NOTE 10: CONCENTRATION OF CREDIT RISK   Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At June 30, 2018 and December 31, 2017, the Company had $14,986,736 and $6,967,469 in excess of the FDIC insured limit, respectively.

1557163

Basis of Presentation:   The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. They do not include all information and notes required by GAAP for complete financial statements. However, except as disclosed herein, there has been no material change in the information disclosed in the Notes to Consolidated Financial Statements included in the Annual Report on Form 10-K of the Company for the year ended December 31, 2017.   In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018.   On April 20, 2018, the Company completed a 1-for-12 reverse stock split of the shares of the Company’s common stock (the “Reverse Stock Split”). As a result of the Reverse Stock Split, every 12 shares of issued and outstanding common stock were combined into one issued and outstanding share of common stock, and the par value per share was changed to $0.18 per share. The number of authorized shares of common stock was not reduced as a result of the Reverse Stock Split. The Company’s common stock began trading on a reverse stock split-adjusted basis on April 20, 2018. All share and per share data included in this report has been retroactively restated to reflect the Reverse Stock Split.

Use of Estimates:   The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Prepaid expenses consisted of the following:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center">June 30, 2018</td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center">December 31, 2017</td> <td style="font-weight: bold; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Prepaid insurance</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right">148,284</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right">125,056</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Retainer and security deposits</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">16,718</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">14,218</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Professional services</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">110,094</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">97,788</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Prepaid research and development</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">115,014</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Financial exchange fees</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">27,500</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Other</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">22,779</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">13,882</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Total prepaid expenses</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">440,389</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">250,944</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Payroll liabilities consisted of the following:    <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center">June 30, 2018</td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center">December 31, 2017</td> <td style="font-weight: bold; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Accrued bonus payable</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right">662,512</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right">566,000</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Accrued vacation</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">167,174</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">147,861</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Accrued payroll liabilities</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">122,971</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">71,006</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: left">Total payroll liabilities</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">952,657</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">784,867</td></tr> </table>

As of June 30, 2018, warrants to purchase 4,760,270 shares of common stock were outstanding including:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Outstanding Warrants to Purchase Shares</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Expiration Date</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>2014 public offering</td> <td> </td> <td> </td> <td style="text-align: right">6,483</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">$540.00</td> <td> </td> <td> </td> <td style="text-align: right">January 29, 2019</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Placement agent fees for Company’s offerings</td> <td> </td> <td> </td> <td style="text-align: right">1,231</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">381.60 – 1,044.00</td> <td> </td> <td> </td> <td style="text-align: right">August - November, 2018</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>2017 Warrant A private placement</td> <td> </td> <td> </td> <td style="text-align: right">441,670</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3.78</td> <td> </td> <td> </td> <td style="text-align: right">August 22, 2018</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">2017 Warrant B private placement</td> <td style="padding-bottom: 1pt"> </td> <td> </td> <td style="text-align: right">441,670</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: right">3.78</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: right">December 22, 2018</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">2018 Warrants</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3,869,216</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: right">4.05</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: right">May 30, 2022</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">4,760,270</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td></tr> </table>

The following table presents the automatic additions to the 2010 Plan since inception pursuant to the “evergreen” terms of the 2010 Plan:    <table cellspacing="0" cellpadding="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">January 1,</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Number of shares</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 86%; padding-left: 9pt">2012</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">2,502</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 9pt">2013</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,871</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 9pt">2014</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,128</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 9pt">2015</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,463</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 9pt">2016</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">18,368</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 9pt">2017</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">12,623</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 9pt">2018</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">106,076</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 9pt">Total additional shares</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">152,031</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

The fair value of stock options granted for the six months ended June 30, 2018 and 2017 was calculated using the Black-Scholes option-pricing model applying the following assumptions:    <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Period ended June 30,</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td> </td> <td colspan="2" nowrap="nowrap" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" nowrap="nowrap" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%">Risk free interest rate</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">2.47% - 2.71%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">1.86% - 2.04%</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expected term</td> <td> </td> <td> </td> <td style="text-align: right">5.24- 5.57 years</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5.32- 6.36 years</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Dividend yield</td> <td> </td> <td> </td> <td style="text-align: right">- % </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">- % </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expected volatility</td> <td> </td> <td> </td> <td style="text-align: right">108.81% - 126.43%</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">112.86% - 114.19%</td></tr> </table>

The fair value of liability options granted for the six months ended June 30, 2018 was calculated using the Black-Scholes option-pricing model applying the following assumptions:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">Six months ended June 30,</td> <td style="white-space: nowrap; padding-bottom: 1pt"> </td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">2018</td> <td style="white-space: nowrap; padding-bottom: 1pt"> </td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td> <td> </td> <td colspan="2" style="white-space: nowrap; text-align: right"> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%">Risk free interest rate</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 15%; text-align: right"> 2.71%</td> <td style="width: 1%"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected term</td> <td> </td> <td> </td> <td style="text-align: right">5.0 years</td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Dividend yield</td> <td> </td> <td> </td> <td style="text-align: right">- % </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expected volatility</td> <td> </td> <td> </td> <td style="text-align: right">125.0%</td> <td> </td></tr></table>

NOTE 9: INCOME TAXES   Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.   As a result of the Company’s cumulative losses, management has concluded that a full valuation allowance against the Company’s net deferred tax assets is appropriate. No income tax liabilities existed as of June 30, 2018 and December 31, 2017 due to the Company’s continuing operating losses.

0.001

10000000

4000

25000

4000

25000

5802

0.18

175000000

4874099

2651952

4874099

2651952

5802

2651952

4874099

13400000

148284

125056

16718

14218

110094 97788 115014 27500

22779

13882

662512

566000

167174

147861

122971

71006

The Company completed a 1-for-12 reverse stock split of the shares of the Company’s common stock (the “Reverse Stock Split”). As a result of the Reverse Stock Split, every 12 shares of issued and outstanding common stock were combined into one issued and outstanding share of common stock, and the par value per share was changed to $0.18 per share.

Australia offers an R&D cash rebate of $0.435 per dollar spent on qualified R&D activities incurred in the country.

4760270

6483

1231

441670

3869216

540.00

381.60

1044.00

3.78

4.05

4.048

2019-01-29 2018-08-31 2018-11-30 2018-08-22 2018-12-22 2018-05-30

2239136

428264

3377129

200954

900367

2275808

93464

182030

511650

787144

187391

452671

1599074

62841

91518

273905

250000

14986736

6967469

4930

3500000

152031

2502

2871

4128

5463

18368

12623

106076

0.0271

0.0247

0.0271

0.0186

0.0204

P5Y

P5Y2M26D

P5Y6M25D

1.250

1.0881

1.2643

1.1286

1.1419

783840

172510

611668

2300000

700000

338

82536

783840

12.70

49.27

2.39

2.38

5.64

P8Y2M8D

P9Y8M12D

17838

73193

1557163

179050

181408

877329

477342

5234116

12290551

3871636

2600

900488

1612416

25000

13624

1000

1 284

13624

3869216

13624

3.52

12290551

1230

12290537

Warrants for $0.18 per warrant if the volume-weighted-average-price of our common stock equals or exceeds $10.56 per share for ten consecutive trading days.

2222147

7822

Twenty-five percent of the options have vested as of the grant date, 50% of the options will vest quarterly over two years, and the remaining 25% will vest upon achievement of certain milestones related to clinical trial progress.

P9Y8M12D

-4782100

4782100

4782100 -4782100

-8

-7056421

399987

6656442

-7822

2222147

-39703 -39703

394189

1333449

2864033

470139

3073803

623004

-3.77

-13.85

-2.90

-7.72

-10799059

-6513175

-8924677

-4809621

4782100

2568132

4782100

2568132

-6016959

-3945043

-4142577

-2241489

138

192817 192817 152447 152447

-6017097

-3599854

-4142656

-1896263

6017097

3599854

4142656

1896263

4078385

2231458

2674920

1072169

The following table sets forth the number of potential common shares excluded from the calculation of net loss per diluted share for the three and six months ended June 30, 2018 and 2017 because including them would be anti-dilutive:     <table cellspacing="0" cellpadding="0" style="font: 10pt/normal Times New Roman, Times, Serif; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="text-align: center; font-weight: bold; border-bottom: black 1pt solid">Three Months Ended   June 30,</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="text-align: center; font-weight: bold; border-bottom: black 1pt solid">Six Months Ended June 30,</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: black 1pt solid">2018</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: black 1pt solid">2017</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: black 1pt solid">2018</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: black 1pt solid">2017</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 48%; text-align: left">Options to purchase common stock</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 10%; text-align: right">200,954</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 10%; text-align: right">93,464</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 10%; text-align: right">187,391</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 10%; text-align: right">62,841</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Series A convertible preferred stock</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">182,030</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">91,518</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left">Series B convertible preferred stock</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">900,367</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">452,671</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 1pt">Warrants to purchase common stock</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">2,275,808</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">511,650</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">1,599,074</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">273,905</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double"> </td> <td style="text-align: right; border-bottom: black 2.5pt double">3,377,129</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double"> </td> <td style="text-align: right; border-bottom: black 2.5pt double">787,144</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double"> </td> <td style="text-align: right; border-bottom: black 2.5pt double">2,239,136</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: black 2.5pt double"> </td> <td style="text-align: right; border-bottom: black 2.5pt double">428,264</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

NOTE 8: NET LOSS PER SHARE   The Company accounts for and discloses net income (loss) per common share in accordance with ASC Topic 260, Earnings Per Share. Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. In addition, in computing the dilutive effect of convertible securities, the numerator is adjusted to add back any convertible preferred dividends. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of potential future exercises of outstanding stock options and common stock warrants. Because the inclusion of potential common shares would be anti-dilutive for all periods presented they have been excluded from the calculation.   The following table summarizes the Company’s calculation of net loss per common share:  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="6" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">Three Months Ended June 30,</td> <td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="6" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">Six Months Ended June 30,</td> <td style="white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">2018</td> <td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">2017</td> <td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">2018</td> <td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">2017</td> <td style="white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Net Loss Per share</td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.25in; text-indent: -8.65pt">Numerator</td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; padding-left: 25.9pt; text-indent: -8.65pt">Net loss</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">(4,142,577</td> <td style="width: 1%">) </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">(2,241,489</td> <td style="width: 1%">) </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">(6,016,959)</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">(3,945,043</td> <td style="width: 1%">) </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 25.9pt; text-indent: -8.65pt">Deemed dividend attributable to preferred stock</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(4,782,100</td> <td style="padding-bottom: 1pt">) </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(2,568,132</td> <td style="padding-bottom: 1pt">) </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(4,782,100)</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(2,568,132</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 25.9pt; text-indent: -8.65pt">Net loss attributable to common shareholders</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">(8,924,677</td> <td style="padding-bottom: 1pt">) </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">(4,809,621</td> <td style="padding-bottom: 1pt">) </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">(10,799,059)</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">(6,513,175</td> <td style="padding-bottom: 1pt">) </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 17.3pt; text-indent: -8.65pt">Denominator</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 25.9pt; text-indent: -8.65pt">Weighted average common shares outstanding</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3,073,803</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">623,004</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">2,864,033</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">470,139</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 25.9pt; text-indent: -8.65pt">Basic and diluted net loss per share</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(2.90</td> <td style="padding-bottom: 2.5pt">) </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(7.72</td> <td style="padding-bottom: 2.5pt">) </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(3.77</td> <td style="padding-bottom: 2.5pt">) </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(13.85</td> <td style="padding-bottom: 2.5pt">) </td></tr> </table>   The following table sets forth the number of potential common shares excluded from the calculation of net loss per diluted share for the three and six months ended June 30, 2018 and 2017 because including them would be anti-dilutive:    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended   June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left">Options to purchase common stock</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">200,954</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">93,464</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">187,391</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">62,841</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series A convertible preferred stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">182,030</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">91,518</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series B convertible preferred stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">900,367</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">452,671</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Warrants to purchase common stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,275,808</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">511,650</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,599,074</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">273,905</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">3,377,129</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">787,144</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,239,136</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">428,264</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   For the three and six months ended June 30, 2018 and 2017, the average price of our common stock was less than the exercise price of the vested stock options and exercisable warrants.

The following table summarizes the Company’s calculation of net loss per common share:  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="6" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">Three Months Ended June 30,</td> <td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="6" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">Six Months Ended June 30,</td> <td style="white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">2018</td> <td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">2017</td> <td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">2018</td> <td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">2017</td> <td style="white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Net Loss Per share</td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.25in; text-indent: -8.65pt">Numerator</td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; padding-left: 25.9pt; text-indent: -8.65pt">Net loss</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">(4,142,577</td> <td style="width: 1%">) </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">(2,241,489</td> <td style="width: 1%">) </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">(6,016,959)</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">(3,945,043</td> <td style="width: 1%">) </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 25.9pt; text-indent: -8.65pt">Deemed dividend attributable to preferred stock</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(4,782,100</td> <td style="padding-bottom: 1pt">) </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(2,568,132</td> <td style="padding-bottom: 1pt">) </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(4,782,100)</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(2,568,132</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 25.9pt; text-indent: -8.65pt">Net loss attributable to common shareholders</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">(8,924,677</td> <td style="padding-bottom: 1pt">) </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">(4,809,621</td> <td style="padding-bottom: 1pt">) </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">(10,799,059)</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">(6,513,175</td> <td style="padding-bottom: 1pt">) </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 17.3pt; text-indent: -8.65pt">Denominator</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 25.9pt; text-indent: -8.65pt">Weighted average common shares outstanding</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3,073,803</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">623,004</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">2,864,033</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">470,139</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 25.9pt; text-indent: -8.65pt">Basic and diluted net loss per share</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(2.90</td> <td style="padding-bottom: 2.5pt">) </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(7.72</td> <td style="padding-bottom: 2.5pt">) </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(3.77</td> <td style="padding-bottom: 2.5pt">) </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(13.85</td> <td style="padding-bottom: 2.5pt">) </td></tr></table>

NOTE 11: COMMITMENTS AND CONTINGENCIES    Lease Commitments    The Company has a commitment under an operating lease to pay future minimum lease payments of $4,930, all of which is due in the year ending December 31, 2018.    Litigation and Contingencies    On October 10, 2013, a putative securities class action complaint, captioned Cook v. Atossa Genetics, Inc., et al., No. 2:13-cv-01836-RSM, was filed in the United States District Court for the Western District of Washington against us, certain of our directors and officers and the underwriters of our November 2012 initial public offering. The complaint alleged that all defendants violated Sections 11 and 12(a)(2), and that we and certain of our directors and officers violated Section 15, of the Securities Act by making material false and misleading statements and omissions in the offering’s registration statement, and that we and certain of our directors and officers violated Sections 10(b) and 20A of the Exchange Act and SEC Rule 10b-5 promulgated thereunder by making false and misleading statements and omissions in the registration statement and in certain of our subsequent press releases and SEC filings with respect to our NAF specimen collection process, our ForeCYTE Breast Health Test and our MASCT device. The complaint sought, on behalf of persons who purchased our common stock between November 8, 2012 and October 4, 2013, inclusive, damages of an unspecific amount.   On March 23, 2018, the parties filed a stipulation of settlement with the court to settle the matter for $3.5 million, completely funded by defendants’ insurers, and on July 20, 2018 the Court approved the settlement.   We are subject to other legal proceedings and claims that arise in the normal course of business. We believe these matters are either without merit or of a kind that should not have a material effect, individually or in the aggregate, on our financial position, results of operations or cash flows.

Recently Issued Accounting Pronouncements:   In February 2016, Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Lease Accounting Topic 842. This ASU requires a lessee to recognize lease assets and liabilities on the balance sheet for all arrangements with terms longer than 12 months. The new standard applies a right-of-use (ROU) model that requires a lessee to record, for all leases with a lease term of more than 12 months, an asset representing its right to use the underlying asset for the lease term and a liability to make lease payments. The lease term is the non-cancellable period of the lease, and includes both periods covered by an option to extend the lease, if the lessee is reasonably certain to exercise that option, and periods covered by an option to terminate the lease, if the lessee is reasonably certain not to exercise that termination option. For leases with a lease term of 12 months or less, a practical expedient is available whereby a lessee may elect, by class of underlying asset, not to recognize an ROU asset or lease liability. A lessee making this accounting policy election would recognize lease expense over the term of the lease, generally in a straight-line pattern. The lessor accounting remains largely consistent with existing GAAP. The new standard takes effect in 2019 for public business entities. The Company has not adopted the provisions of ASU No. 2016-02 and is currently evaluating the impact of adopting ASU 2016-02 on its consolidated financial statements.   In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows, amending the presentation of restricted cash within the statement of cash flows. The new guidance requires that restricted cash be included within cash and cash equivalents on the statement of cash flows. The Company adopted the provisions of ASU No. 2016-18 as of January 1, 2018 and has included restricted cash with cash and cash equivalents on the accompanying statement of cash flows, including reclassifying 2017 balances. For the three and six months ended June 30, 2018 and June 30, 2017, we included $55,000 of restricted cash in cash and cash equivalents on the statement of cash flows. The restricted cash represents a required deposit for the Company credit card and is restricted until the Company no longer has the credit card or the limit changes on the credit card.   In July 2017, the FASB issued ASU 2017-11, Accounting for Certain Financial Instruments with Down Round Features and Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Part I of this ASU addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of future equity offerings. Current accounting guidance requires financial instruments with down round features to be accounted for at fair value. Part II of the Update applies only to nonpublic companies and is therefore not applicable to the Company. The amendments in Part I of the Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. This Update is effective for public entities for fiscal years beginning after December 15, 2018. Early adoption is permitted. The Company early adopted the provisions of ASU No. 2017-11 as of January 1, 2018. As the Company does not have any financial instruments with down round features outstanding as of June 30, 2018, this ASU did not have a material impact on the financial statements upon adoption.   In June 2018, The FASB issued ASU 2018-07, Compensation-Stock Compensation Improvements to Nonemployee Share Based Payment Accounting. This ASU simplifies several aspects of the accounting for non-employee share-based payment transactions resulting from expanding the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide financing to the issuer or was granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers. This update is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted. The Company early adopted the provisions of ASU No. 2018-17 as of April 1, 2018 and it did not have a material impact on the financial statements upon adoption.

55000 55000

NOTE 12: STOCK BASED COMPENSATION   Stock Option and Incentive Plan   On September 28, 2010, the Board of Directors approved the adoption of the 2010 Stock Option and Incentive Plan the (“2010 Plan”) to provide for the grant of equity-based awards to employees, officers, non-employee directors and other key persons providing services to the Company. Awards of incentive options may be granted under the 2010 Plan until September 2020. No other awards may be granted under the 2010 Plan after the date that is 10 years from the date of stock-holder approval. An aggregate of 5,556 shares were initially reserved for issuance in connection with awards granted under the 2010 Plan and on May 18, 2016, an additional 11,111 shares were reserved for issuance under the 2010 Plan. On May 9, 2017, the stockholders approved an additional 125,000 shares for issuance under the 2010 Plan. On April 12, 2018, the stockholders approved an additional 500,000 shares for issuance under the 2010 Plan. The following table presents the automatic additions to the 2010 Plan since inception pursuant to the “evergreen” terms of the 2010 Plan:   <table cellspacing="0" cellpadding="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">January 1,</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Number of shares</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="padding-left: 9pt; width: 86%">2012</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: right; width: 10%">2,502</td> <td style="width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-left: 9pt">2013</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,871</td> <td> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="padding-left: 9pt">2014</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,128</td> <td> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-left: 9pt">2015</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,463</td> <td> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="padding-left: 9pt">2016</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">18,368</td> <td> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-left: 9pt">2017</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">12,623</td> <td> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="padding-bottom: 1pt; padding-left: 9pt">2018</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">106,076</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 2.5pt; padding-left: 9pt">Total additional shares</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">152,031</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>    The Company granted 611,668 options to purchase shares of common stock under the 2010 Plan during the six months ended June 30, 2018. No options were exercised during the three or six months ended June 30, 2018. There are 3,118 shares available for grant under the 2010 Plan as of June 30, 2018.   Compensation costs associated with the Company’s stock options are recognized, based on the grant-date fair values of these options, over the requisite service period, or vesting period. Accordingly, the Company recognized stock-based compensation expense of $179,050 and $181,408 for the three months ended June 30, 2018 and 2017, respectively and $394,189 and $336,116 for the six months ended June 30, 2018 and 2017, respectively (excluding the liability options discussed below). The fair value of stock options granted for the six months ended June 30, 2018 and 2017 was calculated using the Black-Scholes option-pricing model applying the following assumptions:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center; white-space: nowrap"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center; white-space: nowrap">Period ended June 30,</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; white-space: nowrap"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; white-space: nowrap">2018</td> <td style="padding-bottom: 1pt; white-space: nowrap"> </td> <td style="padding-bottom: 1pt; white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; white-space: nowrap">2017</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td> <td> </td> <td colspan="2" style="text-align: right; white-space: nowrap"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right; white-space: nowrap"> </td> <td> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="width: 68%">Risk free interest rate</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: right; width: 13%">2.47% - 2.71%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: right; width: 13%">1.86% - 2.04%</td> <td style="width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Expected term</td> <td> </td> <td> </td> <td style="text-align: right">5.24- 5.57 years</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5.32- 6.36 years</td> <td> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Dividend yield</td> <td> </td> <td> </td> <td style="text-align: right">- % </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">- % </td> <td> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td>Expected volatility</td> <td> </td> <td> </td> <td style="text-align: right">108.81% - 126.43%</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">112.86% - 114.19%</td> <td> </td></tr> </table>   Options issued and outstanding as of June 30, 2018 under the 2010 Plan and their activities during the six months then ended are as follows:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Number of Underlying Shares</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Weighted- Average Exercise Price Per Share</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Weighted- Average Contractual Life Remaining in Years</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Aggregate Intrinsic Value</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="width: 48%">Outstanding as of January 1, 2018</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%">172,510</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 10%">49.27</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 10%"> </td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-left: 9pt">Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">611,668</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2.39</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="padding-left: 9pt">Forfeited</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(338</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">5.64</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 1pt; padding-left: 9pt">Expired</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="padding-bottom: 2.5pt">Outstanding as of June 30, 2018</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">783,840</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right">12.70</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.67</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 2.5pt">Exercisable as of June 30, 2018</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">82,536</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right">93.84</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right">8.19</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt">Vested and expected to vest</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">783,840</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right">12.70</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.67</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>   At June 30, 2018, there were 701,304 unvested options outstanding and the related unrecognized total compensation cost associated with these options was approximately $1,810,227. This expense is expected to be recognized over a weighted-average period of 1.71 years.   Option Grants Classified as Liabilities (“Liability Grants”)   On June 27, 2018, the Company issued option awards to Dr. Steven C. Quay, Chairman of the Board, President and Chief Executive Officer and Kyle Guse, Chief Financial Officer, General Counsel and Secretary. The Company granted Dr. Quay 2,300,000 options and granted Mr. Guse 700,000 options, each exercisable for an equivalent number of shares of Company common stock. The options were granted pursuant to an option award agreement and were granted outside the Company’s 2010 Plan; however, they are subject to the terms and conditions of the 2010 Plan.     The Liability Grants are exercisable for shares of common stock at an exercise price of $2.38 per share, which was the fair market value on the date of grant. The options have an exercise period of ten years from their date of issuance. If at the time the options are exercised the Company cannot deliver shares of common stock to the optionee including, for example, if there are insufficient shares available under the Plan at the time of exercise, then in lieu of the optionee paying the exercise price and the Company issuing shares of stock, the option may only be exercised on a cash “net basis” so that the Company will pay cash in an amount equal to the excess of the fair market value of the common stock over the option exercise price. There currently are not sufficient shares available under the Plan and the Company would be obligated to settle these options in cash if they were exercised. Because these options contain provisions that could require the Company to settle the options in cash in an event outside the Company’s control, they are accounted for as liabilities.   The Liability Grants are subject to vesting requirements. Twenty-five percent of the options have vested as of the grant date, 50% of the options will vest quarterly over two years, and the remaining 25% will vest upon achievement of certain milestones related to clinical trial progress.   Compensation costs associated with the Liability Grants are initially recognized, based on the grant-date fair values of these options, over the requisite or vesting period for time-based options or when it is probable the performance criteria will be achieved for options that vest based on performance. Compensation cost is remeasured each period based on the market value of our underlying stock until award vesting or settlement.   For the three and six months ended June 30, 2018, the Company recognized compensation expense related to these options of $1,557,163.   The fair value of liability options granted for the six months ended June 30, 2018 was calculated using the Black-Scholes option-pricing model applying the following assumptions:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center; white-space: nowrap"> </td> <td style="padding-bottom: 1pt; white-space: nowrap"> </td> <td colspan="2" style="text-align: center; white-space: nowrap">Six months ended June 30,</td> <td style="padding-bottom: 1pt; white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; white-space: nowrap"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; white-space: nowrap">2018</td> <td style="padding-bottom: 1pt; white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td> <td> </td> <td colspan="2" style="text-align: right; white-space: nowrap"> </td> <td> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="width: 82%">Risk free interest rate</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: right; width: 15%"> 2.71%</td> <td style="width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Expected term</td> <td> </td> <td> </td> <td style="text-align: right">5.0 years</td> <td> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Dividend yield</td> <td> </td> <td> </td> <td style="text-align: right">- % </td> <td> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td>Expected volatility</td> <td> </td> <td> </td> <td style="text-align: right">125.0%</td> <td> </td></tr> </table>

Options issued and outstanding as of June 30, 2018 under the 2010 Plan and their activities during the six months then ended are as follows:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Number of Underlying Shares</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Weighted- Average Exercise Price Per Share</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Weighted- Average Contractual Life Remaining in Years</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Aggregate Intrinsic Value</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="width: 48%">Outstanding as of January 1, 2018</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%">172,510</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 10%">49.27</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 10%"> </td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-left: 9pt">Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">611,668</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2.39</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="padding-left: 9pt">Forfeited</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(338</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">5.64</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 1pt; padding-left: 9pt">Expired</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="padding-bottom: 2.5pt">Outstanding as of June 30, 2018</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">783,840</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right">12.70</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.67</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 2.5pt">Exercisable as of June 30, 2018</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">82,536</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right">93.84</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right">8.19</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt">Vested and expected to vest</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">783,840</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right">12.70</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.67</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

93.84

12.70

NOTE 3: SUMMARY OF ACCOUNTING POLICIES   Basis of Presentation:   The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. They do not include all information and notes required by GAAP for complete financial statements. However, except as disclosed herein, there has been no material change in the information disclosed in the Notes to Consolidated Financial Statements included in the Annual Report on Form 10-K of the Company for the year ended December 31, 2017.   In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018.   On April 20, 2018, the Company completed a 1-for-12 reverse stock split of the shares of the Company’s common stock (the “Reverse Stock Split”). As a result of the Reverse Stock Split, every 12 shares of issued and outstanding common stock were combined into one issued and outstanding share of common stock, and the par value per share was changed to $0.18 per share. The number of authorized shares of common stock was not reduced as a result of the Reverse Stock Split. The Company’s common stock began trading on a reverse stock split-adjusted basis on April 20, 2018. All share and per share data included in this report has been retroactively restated to reflect the Reverse Stock Split.   Use of Estimates:   The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.   Recently Issued Accounting Pronouncements:   In February 2016, Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Lease Accounting Topic 842. This ASU requires a lessee to recognize lease assets and liabilities on the balance sheet for all arrangements with terms longer than 12 months. The new standard applies a right-of-use (ROU) model that requires a lessee to record, for all leases with a lease term of more than 12 months, an asset representing its right to use the underlying asset for the lease term and a liability to make lease payments. The lease term is the non-cancellable period of the lease, and includes both periods covered by an option to extend the lease, if the lessee is reasonably certain to exercise that option, and periods covered by an option to terminate the lease, if the lessee is reasonably certain not to exercise that termination option. For leases with a lease term of 12 months or less, a practical expedient is available whereby a lessee may elect, by class of underlying asset, not to recognize an ROU asset or lease liability. A lessee making this accounting policy election would recognize lease expense over the term of the lease, generally in a straight-line pattern. The lessor accounting remains largely consistent with existing GAAP. The new standard takes effect in 2019 for public business entities. The Company has not adopted the provisions of ASU No. 2016-02 and is currently evaluating the impact of adopting ASU 2016-02 on its consolidated financial statements.   In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows, amending the presentation of restricted cash within the statement of cash flows. The new guidance requires that restricted cash be included within cash and cash equivalents on the statement of cash flows. The Company adopted the provisions of ASU No. 2016-18 as of January 1, 2018 and has included restricted cash with cash and cash equivalents on the accompanying statement of cash flows, including reclassifying 2017 balances. For the three and six months ended June 30, 2018 and June 30, 2017, we included $55,000 of restricted cash in cash and cash equivalents on the statement of cash flows. The restricted cash represents a required deposit for the Company credit card and is restricted until the Company no longer has the credit card or the limit changes on the credit card.   In July 2017, the FASB issued ASU 2017-11, Accounting for Certain Financial Instruments with Down Round Features and Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Part I of this ASU addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of future equity offerings. Current accounting guidance requires financial instruments with down round features to be accounted for at fair value. Part II of the Update applies only to nonpublic companies and is therefore not applicable to the Company. The amendments in Part I of the Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. This Update is effective for public entities for fiscal years beginning after December 15, 2018. Early adoption is permitted. The Company early adopted the provisions of ASU No. 2017-11 as of January 1, 2018. As the Company does not have any financial instruments with down round features outstanding as of June 30, 2018, this ASU did not have a material impact on the financial statements upon adoption.   In June 2018, The FASB issued ASU 2018-07, Compensation-Stock Compensation Improvements to Nonemployee Share Based Payment Accounting. This ASU simplifies several aspects of the accounting for non-employee share-based payment transactions resulting from expanding the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide financing to the issuer or was granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers. This update is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted. The Company early adopted the provisions of ASU No. 2018-17 as of April 1, 2018 and it did not have a material impact on the financial statements upon adoption.

EX-101.SCH 7 atos-20180630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - NATURE OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - SUMMARY OF ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - PREPAID EXPENSES link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - RESEARCH AND DEVELOPMENT TAX REBATE RECEIVABLE link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - PAYROLL LIABILITIES link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - NET LOSS PER SHARE link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - CONCENTRATION OF CREDIT RISK link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - STOCK BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - PREPAID EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - PAYROLL LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - NET LOSS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - STOCK BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - PREPAID EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - RESEARCH AND DEVELOPMENT TAX REBATE RECEIVABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - PAYROLL LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - STOCKHOLDERS' EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - NET LOSS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - NET LOSS PER SHARE (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - CONCENTRATION OF CREDIT RISK (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - STOCK BASED COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - STOCK BASED COMPENSATION (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - STOCK BASED COMPENSATION (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - STOCK BASED COMPENSATION (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - STOCK BASED COMPENSATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 atos-20180630_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 atos-20180630_def.xml XBRL DEFINITION FILE EX-101.LAB 10 atos-20180630_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series A convertible preferred Stock [Member] Series B convertible preferred Stock [Member] Reverse Stock Split [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Consolidated Entities [Axis] Atossa Genetics AUS Pty Ltd [Member] Plan Name [Axis] 2014 Public Offering [Member] Placement Agent Fee [Member] Range [Axis] Minimum [Member] Maximum [Member] 2017 Warrant A Private Placement [Member] 2017 Warrant B Private Placement [Member] 2018 Warrants [Member] 2018 Warrant [Member] Antidilutive Securities [Axis] Equity Option [Member] Warrant [Member] Series A Preferred Stock [Member] 2012 [Member] 2013 [Member] 2014 [Member] 2015 [Member] 2016 [Member] 2017 [Member] 2018 [Member] Sale of Stock [Axis] Subscription Rights [Member] Equity Components [Axis] Class of Warrant or Right [Axis] Common Stock [Member] 2010 Plan [Member] Related Party [Axis] Dr. Steven C. Quay [Member] Kyle Guse [Member] Series B Convertible Preferred Stock [Member] Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Accumulated Deficit [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Trading Symbol Document Period End Date Amendment Flag Current Fiscal Year End Date Entity a Well-known Seasoned Issuer Entity a Voluntary Filer Entity's Reporting Status Current Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] Assets Current assets Cash and cash equivalents Restricted cash Prepaid expenses Research and development tax rebate receivable Other current assets Total current assets Furniture and equipment, net Intangible assets, net Other assets Total assets Liabilities and Stockholders' Equity Current liabilities Accounts payable Accrued expenses Payroll liabilities Stock-based compensation liability Other current liabilities Total current liabilities Commitments and contingencies (note 11) Stockholders' equity Preferred stock - $0.001 par value; 10,000,000 shares authorized, consisting of: Series A convertible preferred stock-$0.001 par value; 4,000 shares authorized, and 0 shares outstanding as of June 30, 2018 and December 31, 2017; Series B convertible preferred stock- $0.001 par value; 25,000 and 0 shares authorized, and 5,802 and 0 shares issued and outstanding, as of June 30, 2018 and December 31, 2017, respectively Additional paid-in capital-Series B convertible preferred stock Common stock - $0.18 par value; 175,000,000 shares authorized, 4,874,099 and 2,651,952 shares issued and outstanding, as of June 30, 2018 and December 31, 2017, respectively Additional paid-in capital Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Statement [Table] Statement [Line Items] Preferred stock, par value (in dollars per share) Preferred stock, authorized Preferred stock, issued Preferred stock, outstanding Common stock, par value (in dollars per share) Common stock, authorized Common stock, issued Common stock, outstanding Income Statement [Abstract] Operating expenses: Research and development General and administrative Total operating expenses Operating loss Change in fair value of common stock warrants Warrant financing expense Other income Loss before income taxes Income taxes Net loss Deemed dividends attributable to preferred stock Net loss applicable to common stockholders Loss per common share - basic and diluted (in dollars per share) Weighted average shares outstanding, basic and diluted (in shares) Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance, beginning Balance, beginning (in shares) Issuance of Series B convertible preferred stock, net of issuance costs of $1,333,449 Issuance of Series B convertible preferred stock, net of issuance costs of $1,333,449 (in shares) Allocation of Series B convertible preferred stock to beneficial conversion feature Deemed Dividend on Series B convertible preferred stock Conversion of Series B convertible preferred stock to common stock Conversion of Series B convertible preferred stock to common stock (in shares) Amortization of commitment shares Compensation cost for stock options granted to executives and employees Net loss Balance, ending Balance, ending (in shares) Statement of Stockholders' Equity [Abstract] Payments of Class A units issuance costs Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Compensation cost for stock options granted Loss on disposal of intangible asset Change in stock-based compensation liability Depreciation and amortization Change in fair value of common stock warrants Warrant financing expense Changes in operating assets and liabilities: Prepaid expenses Research and development tax rebate receivable Other assets Accounts payable Payroll liabilities Accrued expenses Other current liabilities Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES Purchase of furniture and equipment Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from issuance of Class A and Class B Units, net of issuance costs Proceeds from issuance of Series B convertible preferred stock, net of issuance costs Net cash provided by financing activities NET INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, BEGINNING BALANCE CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, ENDING BALANCE NONCASH INVESTING AND FINANCING ACTIVITIES Common stock issued for cashless exercise of common stock warrants Amount receivable for warrant exercise Allocation of Class A and Class B Unit proceeds to warrant liability Amortization of commitment shares Organization, Consolidation and Presentation of Financial Statements [Abstract] NATURE OF OPERATIONS GOING CONCERN Accounting Policies [Abstract] SUMMARY OF ACCOUNTING POLICIES Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Prepaid Expenses Research And Development Tax Rebate Receivable RESEARCH AND DEVELOPMENT TAX REBATE RECEIVABLE Payables and Accruals [Abstract] PAYROLL LIABILITIES Equity [Abstract] STOCKHOLDERS' EQUITY Earnings Per Share [Abstract] NET LOSS PER SHARE Income Tax Disclosure [Abstract] INCOME TAXES Risks and Uncertainties [Abstract] CONCENTRATION OF CREDIT RISK Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Disclosure of Compensation Related Costs, Share-based Payments [Abstract] STOCK BASED COMPENSATION Basis of Presentation Use of Estimates Recently Issued Accounting Pronouncements Schedule of prepaid expenses Schedule of payroll liabilities Schedule of warrants Schedule of earning per share Schedule of antidilutive securities Schedule of automatic additions to the 2010 Plan Schedule of stock options EX-101.PRE 11 atos-20180630_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2018	Aug. 10, 2018
Document And Entity Information
Entity Registrant Name	ATOSSA GENETICS INC
Entity Central Index Key	0001488039
Document Type	10-Q
Trading Symbol	ATOS
Document Period End Date	Jun. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		5,069,599
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2018

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 15,236,736	$ 7,217,469
Restricted cash	55,000	55,000
Prepaid expenses	440,389	250,944
Research and development tax rebate receivable	626,011	358,277
Other current assets	50,035	16,344
Total current assets	16,408,171	7,898,034
Furniture and equipment, net	60,926	11,467
Intangible assets, net	59,882	75,686
Other assets	48,867	178,907
Total assets	16,577,846	8,164,094
Current liabilities
Accounts payable	191,217	334,901
Accrued expenses	286,713	90,105
Payroll liabilities	952,657	784,867
Stock-based compensation liability	1,557,163
Other current liabilities	23,331	15,534
Total current liabilities	3,011,081	1,225,407
Commitments and contingencies (note 11)
Stockholders' equity
Preferred stock - $0.001 par value; 10,000,000 shares authorized, consisting of: Series A convertible preferred stock-$0.001 par value; 4,000 shares authorized, and 0 shares outstanding as of June 30, 2018 and December 31, 2017; Series B convertible preferred stock- $0.001 par value; 25,000 and 0 shares authorized, and 5,802 and 0 shares issued and outstanding, as of June 30, 2018 and December 31, 2017, respectively	6
Additional paid-in capital-Series B convertible preferred stock	5,234,116
Common stock - $0.18 par value; 175,000,000 shares authorized, 4,874,099 and 2,651,952 shares issued and outstanding, as of June 30, 2018 and December 31, 2017, respectively	877,329	477,342
Additional paid-in capital	78,898,602	71,887,674
Accumulated deficit	(71,443,288)	(65,426,329)
Total stockholders' equity	13,566,765	6,938,687
Total liabilities and stockholders' equity	$ 16,577,846	$ 8,164,094

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares	Jun. 30, 2018	Dec. 31, 2017
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized	10,000,000	10,000,000
Common stock, par value (in dollars per share)	$ 0.18	$ 0.18
Common stock, authorized	175,000,000	175,000,000
Common stock, issued	4,874,099	2,651,952
Common stock, outstanding	4,874,099	2,651,952
Series A convertible preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized	4,000	4,000
Preferred stock, issued		0
Preferred stock, outstanding	0	0
Series B convertible preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized	25,000	0
Preferred stock, issued	5,802	0
Preferred stock, outstanding	5,802	0

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Operating expenses:
Research and development	$ 1,467,736	$ 824,094	$ 1,938,712	$ 1,368,396
General and administrative	2,674,920	1,072,169	4,078,385	2,231,458
Total operating expenses	4,142,656	1,896,263	6,017,097	3,599,854
Operating loss	(4,142,656)	(1,896,263)	(6,017,097)	(3,599,854)
Change in fair value of common stock warrants		(152,447)		(152,447)
Warrant financing expense		(192,817)		(192,817)
Other income	79	38	138	75
Loss before income taxes	(4,142,577)	(2,241,489)	(6,016,959)	(3,945,043)
Net loss	(4,142,577)	(2,241,489)	(6,016,959)	(3,945,043)
Deemed dividends attributable to preferred stock	(4,782,100)	(2,568,132)	(4,782,100)	(2,568,132)
Net loss applicable to common stockholders	$ (8,924,677)	$ (4,809,621)	$ (10,799,059)	$ (6,513,175)
Loss per common share - basic and diluted (in dollars per share)	$ (2.90)	$ (7.72)	$ (3.77)	$ (13.85)
Weighted average shares outstanding, basic and diluted (in shares)	3,073,803	623,004	2,864,033	470,139

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) - 6 months ended Jun. 30, 2018 - USD ($)	Series B Convertible Preferred Stock [Member]	Additional Paid-in Capital [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance, beginning at Dec. 31, 2017			$ 477,342	$ 71,887,674	$ (65,426,329)	$ 6,938,687
Balance, beginning (in shares) at Dec. 31, 2017			2,651,952			2,651,952
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of Series B convertible preferred stock, net of issuance costs of $1,333,449	$ 14	$ 12,290,537				$ 12,290,551
Issuance of Series B convertible preferred stock, net of issuance costs of $1,333,449 (in shares)	13,624
Allocation of Series B convertible preferred stock to beneficial conversion feature		(4,782,100)		4,782,100
Deemed Dividend on Series B convertible preferred stock		4,782,100		(4,782,100)
Conversion of Series B convertible preferred stock to common stock	$ (8)	(7,056,421)	$ 399,987	6,656,442
Conversion of Series B convertible preferred stock to common stock (in shares)	(7,822)		2,222,147
Amortization of commitment shares				(39,703)		(39,703)
Compensation cost for stock options granted to executives and employees				394,189		394,189
Net loss					(6,016,959)	(6,016,959)
Balance, ending at Jun. 30, 2018	$ 6	$ 5,234,116	$ 877,329	$ 78,898,602	$ (71,443,288)	$ 13,566,765
Balance, ending (in shares) at Jun. 30, 2018	5,802		4,874,099			4,874,099

XML 17 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical)	6 Months Ended
	Jun. 30, 2018 USD ($)
Statement of Stockholders' Equity [Abstract]
Payments of Class A units issuance costs	$ 1,333,449

XML 18 R7.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (4,142,577)	$ (2,241,489)	$ (6,016,959)	$ (3,945,043)
Compensation cost for stock options granted			394,189	336,115
Loss on disposal of intangible asset				17,695
Change in stock-based compensation liability	179,050	181,408	1,557,163
Depreciation and amortization			17,838	73,193
Change in fair value of common stock warrants		152,447		152,447
Warrant financing expense		192,817		192,817
Changes in operating assets and liabilities:
Prepaid expenses			(189,445)	(56,769)
Research and development tax rebate receivable			(267,734)
Other assets			56,644	25,831
Accounts payable			(143,684)	241,491
Payroll liabilities			167,790	(287,479)
Accrued expenses			196,608	27,053
Other current liabilities			7,797	13,074
Net cash used in operating activities			(4,219,793)	(3,209,575)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of furniture and equipment			(51,491)
Net cash used in investing activities			(51,491)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of Class A and Class B Units, net of issuance costs				3,871,636
Proceeds from issuance of Series B convertible preferred stock, net of issuance costs			12,290,551
Net cash provided by financing activities			12,290,551	3,871,636
NET INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH			8,019,267	662,061
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, BEGINNING BALANCE			7,272,469	3,082,962	$ 3,082,962
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, ENDING BALANCE	$ 15,291,736	$ 3,745,023	15,291,736	$ 3,745,023	$ 7,272,469
NONCASH INVESTING AND FINANCING ACTIVITIES
Common stock issued for cashless exercise of common stock warrants				900,488
Amount receivable for warrant exercise				$ 2,600
Allocation of Class A and Class B Unit proceeds to warrant liability				1,612,416
Amortization of commitment shares			$ 39,703	$ 39,705

XML 19 R8.htm IDEA: XBRL DOCUMENT

NATURE OF OPERATIONS

6 Months Ended

Jun. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NATURE OF OPERATIONS

NOTE 1: NATURE OF OPERATIONS

XML 20 R9.htm IDEA: XBRL DOCUMENT

GOING CONCERN

6 Months Ended

Jun. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

GOING CONCERN

NOTE 2: GOING CONCERN

XML 21 R10.htm IDEA: XBRL DOCUMENT

SUMMARY OF ACCOUNTING POLICIES

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

SUMMARY OF ACCOUNTING POLICIES

NOTE 3: SUMMARY OF ACCOUNTING POLICIES

Basis of Presentation:

Use of Estimates:

Recently Issued Accounting Pronouncements:

XML 22 R11.htm IDEA: XBRL DOCUMENT

PREPAID EXPENSES

6 Months Ended

Jun. 30, 2018

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Prepaid Expenses

NOTE 4: PREPAID EXPENSES

Prepaid expenses consisted of the following:

	June 30, 2018		December 31, 2017
Prepaid insurance	$	148,284	$	125,056
Retainer and security deposits		16,718		14,218
Professional services		110,094		97,788
Prepaid research and development		115,014
Financial exchange fees		27,500
Other		22,779		13,882
Total prepaid expenses	$	440,389	$	250,944

XML 23 R12.htm IDEA: XBRL DOCUMENT

RESEARCH AND DEVELOPMENT TAX REBATE RECEIVABLE

6 Months Ended

Jun. 30, 2018

Research And Development Tax Rebate Receivable

RESEARCH AND DEVELOPMENT TAX REBATE RECEIVABLE

NOTE 5: RESEARCH AND DEVELOPMENT TAX REBATE RECEIVABLE

XML 24 R13.htm IDEA: XBRL DOCUMENT

PAYROLL LIABILITIES

6 Months Ended

Jun. 30, 2018

Payables and Accruals [Abstract]

PAYROLL LIABILITIES

NOTE 6: PAYROLL LIABILITIES

Payroll liabilities consisted of the following:

	June 30, 2018		December 31, 2017
Accrued bonus payable	$	662,512	$	566,000
Accrued vacation		167,174		147,861
Accrued payroll liabilities		122,971		71,006
Total payroll liabilities	$	952,657	$	784,867

XML 25 R14.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY

6 Months Ended

Jun. 30, 2018

Equity [Abstract]

STOCKHOLDERS' EQUITY

NOTE 7: STOCKHOLDERS’ EQUITY

2018 Subscription Rights Offering of Units Consisting of Series B Convertible Preferred Stock and Warrants

Series B Convertible Preferred Stock.

The terms and provisions of our Series B convertible preferred stock are:

Fundamental Transactions. In the event we effect certain mergers, consolidations, sales of substantially all of our assets, tender or exchange offers, reclassifications or share exchanges in which our common stock is effectively converted into or exchanged for other securities, cash or property, we consummate a business combination in which another person acquires 50% of the outstanding shares of our common stock, or any person or group becomes the beneficial owner of 50% of the aggregate ordinary voting power represented by our issued and outstanding common stock, then, upon any subsequent conversion of the Series B convertible preferred stock, the holders of the Series B convertible preferred stock will have the right to receive any shares of the acquiring corporation or other consideration it would have been entitled to receive if it had been a holder of the number of shares of common stock then issuable upon conversion in full of the Series B convertible preferred stock.

Voting Rights. Except as otherwise provided in the certificate of designation or as otherwise required by law, the Series B convertible preferred stock has no voting rights.

2018 Warrants

The terms and conditions of the warrants included in the 2018 rights offering are as follows:

Exchange Listing. We do not intend to apply to list the warrants on any securities exchange or recognized trading system.

Outstanding Warrants

As of June 30, 2018, warrants to purchase 4,760,270 shares of common stock were outstanding including:

	Outstanding Warrants to Purchase Shares		Exercise Price		Expiration Date

2014 public offering		6,483		$540.00	January 29, 2019
Placement agent fees for Company’s offerings		1,231		381.60 – 1,044.00	August - November, 2018
2017 Warrant A private placement		441,670		3.78	August 22, 2018
2017 Warrant B private placement		441,670		3.78	December 22, 2018
2018 Warrants		3,869,216		4.05	May 30, 2022
		4,760,270

Conversion of Series B Convertible Preferred Stock

XML 26 R15.htm IDEA: XBRL DOCUMENT

NET LOSS PER SHARE

6 Months Ended

Jun. 30, 2018

Earnings Per Share [Abstract]

NET LOSS PER SHARE

NOTE 8: NET LOSS PER SHARE

The following table summarizes the Company’s calculation of net loss per common share:


	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
Net Loss Per share
Numerator
Net loss	$	(4,142,577	)	$	(2,241,489	)	$	(6,016,959)		$	(3,945,043	)
Deemed dividend attributable to preferred stock		(4,782,100	)		(2,568,132	)		(4,782,100)			(2,568,132	)
Net loss attributable to common shareholders	$	(8,924,677	)	$	(4,809,621	)	$	(10,799,059)		$	(6,513,175	)
Denominator
Weighted average common shares outstanding		3,073,803			623,004			2,864,033			470,139
Basic and diluted net loss per share	$	(2.90	)	$	(7.72	)	$	(3.77	)	$	(13.85	)

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Options to purchase common stock		200,954		93,464		187,391		62,841
Series A convertible preferred stock				182,030				91,518
Series B convertible preferred stock		900,367				452,671
Warrants to purchase common stock		2,275,808		511,650		1,599,074		273,905
Total		3,377,129		787,144		2,239,136		428,264

For the three and six months ended June 30, 2018 and 2017, the average price of our common stock was less than the exercise price of the vested stock options and exercisable warrants.

XML 27 R16.htm IDEA: XBRL DOCUMENT

INCOME TAXES

6 Months Ended

Jun. 30, 2018

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 9: INCOME TAXES

XML 28 R17.htm IDEA: XBRL DOCUMENT

CONCENTRATION OF CREDIT RISK

6 Months Ended

Jun. 30, 2018

Risks and Uncertainties [Abstract]

CONCENTRATION OF CREDIT RISK

NOTE 10: CONCENTRATION OF CREDIT RISK

XML 29 R18.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES

6 Months Ended

Jun. 30, 2018

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 11: COMMITMENTS AND CONTINGENCIES

Lease Commitments

The Company has a commitment under an operating lease to pay future minimum lease payments of $4,930, all of which is due in the year ending December 31, 2018.

Litigation and Contingencies

XML 30 R19.htm IDEA: XBRL DOCUMENT

STOCK BASED COMPENSATION

6 Months Ended

Jun. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCK BASED COMPENSATION

NOTE 12: STOCK BASED COMPENSATION

Stock Option and Incentive Plan

The following table presents the automatic additions to the 2010 Plan since inception pursuant to the “evergreen” terms of the 2010 Plan:

January 1,	Number of shares
2012		2,502
2013		2,871
2014		4,128
2015		5,463
2016		18,368
2017		12,623
2018		106,076
Total additional shares		152,031

	Period ended June 30,
	2018		2017

Risk free interest rate		2.47% - 2.71%		1.86% - 2.04%
Expected term		5.24- 5.57 years		5.32- 6.36 years

Dividend yield		- %		- %
Expected volatility		108.81% - 126.43%		112.86% - 114.19%

Options issued and outstanding as of June 30, 2018 under the 2010 Plan and their activities during the six months then ended are as follows:

	Number of Underlying Shares			Weighted- Average Exercise Price Per Share		Weighted- Average Contractual Life Remaining in Years		Aggregate Intrinsic Value
Outstanding as of January 1, 2018		172,510		$	49.27			$
Granted		611,668			2.39
Forfeited		(338	)		5.64
Expired
Outstanding as of June 30, 2018		783,840			12.70		9.67	$
Exercisable as of June 30, 2018		82,536			93.84		8.19	$
Vested and expected to vest		783,840			12.70		9.67	$

Option Grants Classified as Liabilities (“Liability Grants”)

For the three and six months ended June 30, 2018, the Company recognized compensation expense related to these options of $1,557,163.

The fair value of liability options granted for the six months ended June 30, 2018 was calculated using the Black-Scholes option-pricing model applying the following assumptions:

	Six months ended June 30,
	2018

Risk free interest rate		2.71%
Expected term		5.0 years

Dividend yield		- %
Expected volatility		125.0%

XML 31 R20.htm IDEA: XBRL DOCUMENT

SUMMARY OF ACCOUNTING POLICIES (Policies)	6 Months Ended
SUMMARY OF ACCOUNTING POLICIES (Policies)	Jun. 30, 2018
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation: The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. They do not include all information and notes required by GAAP for complete financial statements. However, except as disclosed herein, there has been no material change in the information disclosed in the Notes to Consolidated Financial Statements included in the Annual Report on Form 10-K of the Company for the year ended December 31, 2017. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. On April 20, 2018, the Company completed a 1-for-12 reverse stock split of the shares of the Company’s common stock (the “Reverse Stock Split”). As a result of the Reverse Stock Split, every 12 shares of issued and outstanding common stock were combined into one issued and outstanding share of common stock, and the par value per share was changed to $0.18 per share. The number of authorized shares of common stock was not reduced as a result of the Reverse Stock Split. The Company’s common stock began trading on a reverse stock split-adjusted basis on April 20, 2018. All share and per share data included in this report has been retroactively restated to reflect the Reverse Stock Split.
Use of Estimates	Use of Estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements: In February 2016, Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Lease Accounting Topic 842. This ASU requires a lessee to recognize lease assets and liabilities on the balance sheet for all arrangements with terms longer than 12 months. The new standard applies a right-of-use (ROU) model that requires a lessee to record, for all leases with a lease term of more than 12 months, an asset representing its right to use the underlying asset for the lease term and a liability to make lease payments. The lease term is the non-cancellable period of the lease, and includes both periods covered by an option to extend the lease, if the lessee is reasonably certain to exercise that option, and periods covered by an option to terminate the lease, if the lessee is reasonably certain not to exercise that termination option. For leases with a lease term of 12 months or less, a practical expedient is available whereby a lessee may elect, by class of underlying asset, not to recognize an ROU asset or lease liability. A lessee making this accounting policy election would recognize lease expense over the term of the lease, generally in a straight-line pattern. The lessor accounting remains largely consistent with existing GAAP. The new standard takes effect in 2019 for public business entities. The Company has not adopted the provisions of ASU No. 2016-02 and is currently evaluating the impact of adopting ASU 2016-02 on its consolidated financial statements. In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows, amending the presentation of restricted cash within the statement of cash flows. The new guidance requires that restricted cash be included within cash and cash equivalents on the statement of cash flows. The Company adopted the provisions of ASU No. 2016-18 as of January 1, 2018 and has included restricted cash with cash and cash equivalents on the accompanying statement of cash flows, including reclassifying 2017 balances. For the three and six months ended June 30, 2018 and June 30, 2017, we included $55,000 of restricted cash in cash and cash equivalents on the statement of cash flows. The restricted cash represents a required deposit for the Company credit card and is restricted until the Company no longer has the credit card or the limit changes on the credit card. In July 2017, the FASB issued ASU 2017-11, Accounting for Certain Financial Instruments with Down Round Features and Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Part I of this ASU addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of future equity offerings. Current accounting guidance requires financial instruments with down round features to be accounted for at fair value. Part II of the Update applies only to nonpublic companies and is therefore not applicable to the Company. The amendments in Part I of the Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. This Update is effective for public entities for fiscal years beginning after December 15, 2018. Early adoption is permitted. The Company early adopted the provisions of ASU No. 2017-11 as of January 1, 2018. As the Company does not have any financial instruments with down round features outstanding as of June 30, 2018, this ASU did not have a material impact on the financial statements upon adoption. In June 2018, The FASB issued ASU 2018-07, Compensation-Stock Compensation Improvements to Nonemployee Share Based Payment Accounting. This ASU simplifies several aspects of the accounting for non-employee share-based payment transactions resulting from expanding the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide financing to the issuer or was granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers. This update is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted. The Company early adopted the provisions of ASU No. 2018-17 as of April 1, 2018 and it did not have a material impact on the financial statements upon adoption.

XML 32 R21.htm IDEA: XBRL DOCUMENT

PREPAID EXPENSES (Tables)

6 Months Ended

Jun. 30, 2018

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Schedule of prepaid expenses

Prepaid expenses consisted of the following:

	June 30, 2018		December 31, 2017
Prepaid insurance	$	148,284	$	125,056
Retainer and security deposits		16,718		14,218
Professional services		110,094		97,788
Prepaid research and development		115,014
Financial exchange fees		27,500
Other		22,779		13,882
Total prepaid expenses	$	440,389	$	250,944

XML 33 R22.htm IDEA: XBRL DOCUMENT

PAYROLL LIABILITIES (Tables)

6 Months Ended

Jun. 30, 2018

Payables and Accruals [Abstract]

Schedule of payroll liabilities

Payroll liabilities consisted of the following:

	June 30, 2018		December 31, 2017
Accrued bonus payable	$	662,512	$	566,000
Accrued vacation		167,174		147,861
Accrued payroll liabilities		122,971		71,006
Total payroll liabilities	$	952,657	$	784,867

XML 34 R23.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Tables)

6 Months Ended

Jun. 30, 2018

Equity [Abstract]

Schedule of warrants

As of June 30, 2018, warrants to purchase 4,760,270 shares of common stock were outstanding including:

	Outstanding Warrants to Purchase Shares		Exercise Price		Expiration Date

2014 public offering		6,483		$540.00	January 29, 2019
Placement agent fees for Company’s offerings		1,231		381.60 – 1,044.00	August - November, 2018
2017 Warrant A private placement		441,670		3.78	August 22, 2018
2017 Warrant B private placement		441,670		3.78	December 22, 2018
2018 Warrants		3,869,216		4.05	May 30, 2022
		4,760,270

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 35 R24.htm IDEA: XBRL DOCUMENT

NET LOSS PER SHARE (Tables)

6 Months Ended

Jun. 30, 2018

Earnings Per Share [Abstract]

Schedule of earning per share

The following table summarizes the Company’s calculation of net loss per common share:


	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
Net Loss Per share
Numerator
Net loss	$	(4,142,577	)	$	(2,241,489	)	$	(6,016,959)		$	(3,945,043	)
Deemed dividend attributable to preferred stock		(4,782,100	)		(2,568,132	)		(4,782,100)			(2,568,132	)
Net loss attributable to common shareholders	$	(8,924,677	)	$	(4,809,621	)	$	(10,799,059)		$	(6,513,175	)
Denominator
Weighted average common shares outstanding		3,073,803			623,004			2,864,033			470,139
Basic and diluted net loss per share	$	(2.90	)	$	(7.72	)	$	(3.77	)	$	(13.85	)

Schedule of antidilutive securities

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Options to purchase common stock		200,954		93,464		187,391		62,841
Series A convertible preferred stock				182,030				91,518
Series B convertible preferred stock		900,367				452,671
Warrants to purchase common stock		2,275,808		511,650		1,599,074		273,905
Total		3,377,129		787,144		2,239,136		428,264

XML 36 R25.htm IDEA: XBRL DOCUMENT

STOCK BASED COMPENSATION (Tables)

6 Months Ended

Jun. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of automatic additions to the 2010 Plan

The following table presents the automatic additions to the 2010 Plan since inception pursuant to the “evergreen” terms of the 2010 Plan:

January 1,	Number of shares
2012		2,502
2013		2,871
2014		4,128
2015		5,463
2016		18,368
2017		12,623
2018		106,076
Total additional shares		152,031

Schedule of stock options

Options issued and outstanding as of June 30, 2018 under the 2010 Plan and their activities during the six months then ended are as follows:

	Number of Underlying Shares			Weighted- Average Exercise Price Per Share		Weighted- Average Contractual Life Remaining in Years		Aggregate Intrinsic Value
Outstanding as of January 1, 2018		172,510		$	49.27			$
Granted		611,668			2.39
Forfeited		(338	)		5.64
Expired
Outstanding as of June 30, 2018		783,840			12.70		9.67	$
Exercisable as of June 30, 2018		82,536			93.84		8.19	$
Vested and expected to vest		783,840			12.70		9.67	$

Schedule of stock options valuation assumptions

The fair value of stock options granted for the six months ended June 30, 2018 and 2017 was calculated using the Black-Scholes option-pricing model applying the following assumptions:

	Period ended June 30,
	2018		2017

Risk free interest rate		2.47% - 2.71%		1.86% - 2.04%
Expected term		5.24- 5.57 years		5.32- 6.36 years

Dividend yield		- %		- %
Expected volatility		108.81% - 126.43%		112.86% - 114.19%

Schedule of fair value of liability options granted

The fair value of liability options granted for the six months ended June 30, 2018 was calculated using the Black-Scholes option-pricing model applying the following assumptions:

	Six months ended June 30,
	2018

Risk free interest rate		2.71%
Expected term		5.0 years

Dividend yield		- %
Expected volatility		125.0%

XML 37 R26.htm IDEA: XBRL DOCUMENT

GOING CONCERN (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
GOING CONCERN (Details Narrative) - USD ($)	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ (4,142,577)	$ (2,241,489)	$ (6,016,959)	$ (3,945,043)
Cash and cash equivalents	15,236,736		15,236,736		$ 7,217,469
Working capital	$ 13,400,000		13,400,000
Net cash provided by (used in) operating activities			$ (4,219,793)	$ (3,209,575)

XML 38 R27.htm IDEA: XBRL DOCUMENT

SUMMARY OF ACCOUNTING POLICIES (Details Narrative) - USD ($)		6 Months Ended
	Aug. 20, 2018	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Common stock, par or stated value (in dollars per share)		$ 0.18		$ 0.18
Restricted cash and cash equivalents		$ 55,000	$ 55,000
Reverse Stock Split [Member] \| Subsequent Event [Member]
Description of reverse stock split	The Company completed a 1-for-12 reverse stock split of the shares of the Company’s common stock (the “Reverse Stock Split”). As a result of the Reverse Stock Split, every 12 shares of issued and outstanding common stock were combined into one issued and outstanding share of common stock, and the par value per share was changed to $0.18 per share.

XML 39 R28.htm IDEA: XBRL DOCUMENT

PREPAID EXPENSES (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid insurance	$ 148,284	$ 125,056
Retainer and security deposits	16,718	14,218
Professional services	110,094	97,788
Prepaid research and development	115,014
Financial exchange fees	27,500
Other	22,779	13,882
Total prepaid expenses	$ 440,389	$ 250,944

XML 40 R29.htm IDEA: XBRL DOCUMENT

RESEARCH AND DEVELOPMENT TAX REBATE RECEIVABLE (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Research and development expense	$ 1,467,736	$ 824,094	$ 1,938,712	$ 1,368,396
Research and development tax rebate receivable			$ 267,734
Atossa Genetics AUS Pty Ltd [Member]
Description of research and development cash rebate offer			Australia offers an R&D cash rebate of $0.435 per dollar spent on qualified R&D activities incurred in the country.
Research and development expense			$ 616,000
Research and development tax rebate receivable			$ 626,000		$ 268,000

XML 41 R30.htm IDEA: XBRL DOCUMENT

PAYROLL LIABILITIES (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Payables and Accruals [Abstract]
Accrued bonus payable	$ 662,512	$ 566,000
Accrued vacation	167,174	147,861
Accrued payroll liabilities	122,971	71,006
Total payroll liabilities	$ 952,657	$ 784,867

XML 42 R31.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details)	6 Months Ended
STOCKHOLDERS' EQUITY (Details)	Jun. 30, 2018 $ / shares shares
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding \| shares	4,760,270
2014 Public Offering [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding \| shares	6,483
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 540.00
Expiration Dates of Class of Warrant or Right Not Date From Which Warrants or Rights Exercisable	Jan. 29, 2019
Placement Agent Fee [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding \| shares	1,231
Placement Agent Fee [Member] \| Minimum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 381.60
Expiration Dates of Class of Warrant or Right Not Date From Which Warrants or Rights Exercisable	Aug. 31, 2018
Placement Agent Fee [Member] \| Maximum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 1,044.00
Expiration Dates of Class of Warrant or Right Not Date From Which Warrants or Rights Exercisable	Nov. 30, 2018
2017 Warrant A Private Placement [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding \| shares	441,670
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 3.78
Expiration Dates of Class of Warrant or Right Not Date From Which Warrants or Rights Exercisable	Aug. 22, 2018
2017 Warrant B Private Placement [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding \| shares	441,670
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 3.78
Expiration Dates of Class of Warrant or Right Not Date From Which Warrants or Rights Exercisable	Dec. 22, 2018
2018 Warrants [Member]
Class of Warrant or Right [Line Items]
Expiration Dates of Class of Warrant or Right Not Date From Which Warrants or Rights Exercisable	May 30, 2018
2018 Warrant [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding \| shares	3,869,216
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 4.05

XML 43 R32.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details Narrative) - USD ($)			6 Months Ended
STOCKHOLDERS' EQUITY (Details Narrative) - USD ($)	May 30, 2018	May 09, 2018	Jun. 30, 2018	May 29, 2018	Dec. 31, 2017
Preferred stock, par value (in dollars per share)			$ 0.001		$ 0.001
Preferred stock, authorized			10,000,000		10,000,000
Value of shares issued			$ 12,290,551
Series B convertible preferred Stock [Member]
Preferred stock, par value (in dollars per share)				$ 0.001
Preferred stock, authorized				25,000
Number of stock converted			7,822
Number of stock issued upon conversion			2,222,147
Subscription Rights [Member]
Number of units issued	13,624	25,000
Unit price (in dollars per unit)		$ 1,000
Subscription Rights [Member] \| Series B convertible preferred Stock [Member]
Number of shares consist in each unit		1
Number of shares issued	13,624
Stock conversion price (in dollars per share)			$ 3.52
Subscription Rights [Member] \| Common Stock [Member] \| Warrant [Member]
Number of shares consist in each unit		284
Number of shares issued	3,869,216
Number of common stock exercisable	1
Warrant exercise price (in dollars per share)	$ 4.048
Value of shares issued	$ 1,230
Description of warrant redemption rights			Warrants for $0.18 per warrant if the volume-weighted-average-price of our common stock equals or exceeds $10.56 per share for ten consecutive trading days.

XML 44 R33.htm IDEA: XBRL DOCUMENT

NET LOSS PER SHARE (Details) - USD ($)	3 Months Ended		6 Months Ended
NET LOSS PER SHARE (Details) - USD ($)	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Numerator
Net loss	$ (4,142,577)	$ (2,241,489)	$ (6,016,959)	$ (3,945,043)
Deemed dividend attributable to preferred stock	(4,782,100)	(2,568,132)	(4,782,100)	(2,568,132)
Net loss attributable to common shareholders	$ (8,924,677)	$ (4,809,621)	$ (10,799,059)	$ (6,513,175)
Denominator
Weighted average common shares outstanding	3,073,803	623,004	2,864,033	470,139
Basic and diluted net loss per share	$ (2.90)	$ (7.72)	$ (3.77)	$ (13.85)

XML 45 R34.htm IDEA: XBRL DOCUMENT

NET LOSS PER SHARE (Details 1) - shares	3 Months Ended			6 Months Ended
NET LOSS PER SHARE (Details 1) - shares	Jun. 30, 2018	Jun. 30, 2017	Jun. 23, 2017	Jun. 30, 2018	Jun. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of potential common shares excluded	3,377,129		787,144	2,239,136	428,264
Series A Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of potential common shares excluded		182,030			91,518
Series B convertible preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of potential common shares excluded	900,367			452,671
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of potential common shares excluded	200,954	93,464		187,391	62,841
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of potential common shares excluded	2,275,808	511,650		1,599,074	273,905

XML 46 R35.htm IDEA: XBRL DOCUMENT

CONCENTRATION OF CREDIT RISK (Details Narrative) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Risks and Uncertainties [Abstract]
Cash, FDIC insured amount	$ 250,000
Cash, uninsured amount	$ 14,986,736	$ 6,967,469

XML 47 R36.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)		3 Months Ended		6 Months Ended
	Mar. 23, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Operating lease to pay in 2018 future minimum lease payments		$ 4,930		$ 4,930
General and administrative expenses		$ 2,674,920	$ 1,072,169	$ 4,078,385	$ 2,231,458
Amount paid claim settlement	$ 3,500,000

XML 48 R37.htm IDEA: XBRL DOCUMENT

STOCK BASED COMPENSATION (Details)	6 Months Ended
STOCK BASED COMPENSATION (Details)	Jun. 30, 2018 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total additional shares	152,031
2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total additional shares	2,502
2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total additional shares	2,871
2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total additional shares	4,128
2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total additional shares	5,463
2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total additional shares	18,368
2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total additional shares	12,623
2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total additional shares	106,076

XML 49 R38.htm IDEA: XBRL DOCUMENT

STOCK BASED COMPENSATION (Details 1)	6 Months Ended
STOCK BASED COMPENSATION (Details 1)	Jun. 30, 2018	Jun. 30, 2017
Risk free interest rate	2.71%
Expected term	5 years
Expected volatility	125.00%
Minimum [Member]
Risk free interest rate	2.47%	1.86%
Expected term		5 years 2 months 26 days
Expected volatility	108.81%	112.86%
Maximum [Member]
Risk free interest rate	2.71%	2.04%
Expected term		5 years 6 months 25 days
Expected volatility	126.43%	114.19%

XML 50 R39.htm IDEA: XBRL DOCUMENT

STOCK BASED COMPENSATION (Details 2)	6 Months Ended
STOCK BASED COMPENSATION (Details 2)	Jun. 30, 2018 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning \| shares	172,510
Granted \| shares	611,668
Forfeited \| shares	338
Outstanding at ending \| shares	783,840
Exercisable at ending \| shares	82,536
Vested and expected to vest \| shares	783,840
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Rollforward]
Outstanding at beginning \| $ / shares	$ 49.27
Granted \| $ / shares	2.39
Forfeited \| $ / shares	5.64
Outstanding at ending \| $ / shares	12.70
Exercisable at ending \| $ / shares	93.84
Vested and expected to vest \| $ / shares	$ 12.70
Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Contractual Life Remaining in Years [Rollforward]
Outstanding at ending	9 years 8 months 12 days
Exercisable at end	8 years 2 months 8 days
Vested and expected to vest	9 years 8 months 12 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Rollforward]
Outstanding at beginning
Granted
Forfeited
Expired
Outstanding at ending
Exercisable at ending
Vested and expected to vest

XML 51 R40.htm IDEA: XBRL DOCUMENT

STOCK BASED COMPENSATION (Details 3)	6 Months Ended
STOCK BASED COMPENSATION (Details 3)	Jun. 30, 2018
Stock Based Compensation
Risk free interest rate	2.71%
Expected term	5 years
Expected volatility	125.00%

XML 52 R41.htm IDEA: XBRL DOCUMENT

STOCK BASED COMPENSATION (Details Narrative) - USD ($)		3 Months Ended		6 Months Ended
STOCK BASED COMPENSATION (Details Narrative) - USD ($)	Jun. 27, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018
Stock-based compensation expense		$ 179,050	$ 181,408	$ 1,557,163
Number of options granted				611,668
Option exercise price (in dollars per share)				$ 2.39
2010 Plan [Member]
Option exercise price (in dollars per share)		$ 2.38
Description of vesting rights		Twenty-five percent of the options have vested as of the grant date, 50% of the options will vest quarterly over two years, and the remaining 25% will vest upon achievement of certain milestones related to clinical trial progress.
2010 Plan [Member] \| Dr. Steven C. Quay [Member]
Number of options granted	2,300,000
2010 Plan [Member] \| Kyle Guse [Member]
Number of options granted	700,000

EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 54 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 55 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 82 168 1 false 33 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://atossagenetics.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Sheet http://atossagenetics.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Statements 2 false false R3.htm 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Sheet http://atossagenetics.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Sheet http://atossagenetics.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Statements 4 false false R5.htm 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) Sheet http://atossagenetics.com/role/CondensedConsolidatedStatementOfStockholdersEquity CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical) Sheet http://atossagenetics.com/role/CondensedConsolidatedStatementOfStockholdersEquityParenthetical CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical) Statements 6 false false R7.htm 00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://atossagenetics.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 7 false false R8.htm 00000008 - Disclosure - NATURE OF OPERATIONS Sheet http://atossagenetics.com/role/NatureOfOperations NATURE OF OPERATIONS Notes 8 false false R9.htm 00000009 - Disclosure - GOING CONCERN Sheet http://atossagenetics.com/role/GoingConcern GOING CONCERN Notes 9 false false R10.htm 00000010 - Disclosure - SUMMARY OF ACCOUNTING POLICIES Sheet http://atossagenetics.com/role/SummaryOfAccountingPolicies SUMMARY OF ACCOUNTING POLICIES Notes 10 false false R11.htm 00000011 - Disclosure - PREPAID EXPENSES Sheet http://atossagenetics.com/role/PrepaidExpenses PREPAID EXPENSES Notes 11 false false R12.htm 00000012 - Disclosure - RESEARCH AND DEVELOPMENT TAX REBATE RECEIVABLE Sheet http://atossagenetics.com/role/ResearchAndDevelopmentTaxRebateReceivable RESEARCH AND DEVELOPMENT TAX REBATE RECEIVABLE Notes 12 false false R13.htm 00000013 - Disclosure - PAYROLL LIABILITIES Sheet http://atossagenetics.com/role/PayrollLiabilities PAYROLL LIABILITIES Notes 13 false false R14.htm 00000014 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://atossagenetics.com/role/StockholdersEquity STOCKHOLDERS' EQUITY Notes 14 false false R15.htm 00000015 - Disclosure - NET LOSS PER SHARE Sheet http://atossagenetics.com/role/NetLossPerShare NET LOSS PER SHARE Notes 15 false false R16.htm 00000016 - Disclosure - INCOME TAXES Sheet http://atossagenetics.com/role/IncomeTaxes INCOME TAXES Notes 16 false false R17.htm 00000017 - Disclosure - CONCENTRATION OF CREDIT RISK Sheet http://atossagenetics.com/role/ConcentrationOfCreditRisk CONCENTRATION OF CREDIT RISK Notes 17 false false R18.htm 00000018 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://atossagenetics.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 18 false false R19.htm 00000019 - Disclosure - STOCK BASED COMPENSATION Sheet http://atossagenetics.com/role/StockBasedCompensation STOCK BASED COMPENSATION Notes 19 false false R20.htm 00000020 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Policies) Sheet http://atossagenetics.com/role/SummaryOfAccountingPoliciesPolicies SUMMARY OF ACCOUNTING POLICIES (Policies) Policies 20 false false R21.htm 00000021 - Disclosure - PREPAID EXPENSES (Tables) Sheet http://atossagenetics.com/role/PrepaidExpensesTables PREPAID EXPENSES (Tables) Tables http://atossagenetics.com/role/PrepaidExpenses 21 false false R22.htm 00000022 - Disclosure - PAYROLL LIABILITIES (Tables) Sheet http://atossagenetics.com/role/PayrollLiabilitiesTables PAYROLL LIABILITIES (Tables) Tables http://atossagenetics.com/role/PayrollLiabilities 22 false false R23.htm 00000023 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://atossagenetics.com/role/StockholdersEquityTables STOCKHOLDERS' EQUITY (Tables) Tables http://atossagenetics.com/role/StockholdersEquity 23 false false R24.htm 00000024 - Disclosure - NET LOSS PER SHARE (Tables) Sheet http://atossagenetics.com/role/NetLossPerShareTables NET LOSS PER SHARE (Tables) Tables http://atossagenetics.com/role/NetLossPerShare 24 false false R25.htm 00000025 - Disclosure - STOCK BASED COMPENSATION (Tables) Sheet http://atossagenetics.com/role/StockBasedCompensationTables STOCK BASED COMPENSATION (Tables) Tables http://atossagenetics.com/role/StockBasedCompensation 25 false false R26.htm 00000026 - Disclosure - GOING CONCERN (Details Narrative) Sheet http://atossagenetics.com/role/GoingConcernDetailsNarrative GOING CONCERN (Details Narrative) Details http://atossagenetics.com/role/GoingConcern 26 false false R27.htm 00000027 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Details Narrative) Sheet http://atossagenetics.com/role/SummaryOfAccountingPoliciesDetailsNarrative SUMMARY OF ACCOUNTING POLICIES (Details Narrative) Details http://atossagenetics.com/role/SummaryOfAccountingPoliciesPolicies 27 false false R28.htm 00000028 - Disclosure - PREPAID EXPENSES (Details) Sheet http://atossagenetics.com/role/PrepaidExpensesDetails PREPAID EXPENSES (Details) Details http://atossagenetics.com/role/PrepaidExpensesTables 28 false false R29.htm 00000029 - Disclosure - RESEARCH AND DEVELOPMENT TAX REBATE RECEIVABLE (Details Narrative) Sheet http://atossagenetics.com/role/ResearchAndDevelopmentTaxRebateReceivableDetailsNarrative RESEARCH AND DEVELOPMENT TAX REBATE RECEIVABLE (Details Narrative) Details http://atossagenetics.com/role/ResearchAndDevelopmentTaxRebateReceivable 29 false false R30.htm 00000030 - Disclosure - PAYROLL LIABILITIES (Details) Sheet http://atossagenetics.com/role/PayrollLiabilitiesDetails PAYROLL LIABILITIES (Details) Details http://atossagenetics.com/role/PayrollLiabilitiesTables 30 false false R31.htm 00000031 - Disclosure - STOCKHOLDERS' EQUITY (Details) Sheet http://atossagenetics.com/role/StockholdersEquityDetails STOCKHOLDERS' EQUITY (Details) Details http://atossagenetics.com/role/StockholdersEquityTables 31 false false R32.htm 00000032 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative) Sheet http://atossagenetics.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS' EQUITY (Details Narrative) Details http://atossagenetics.com/role/StockholdersEquityTables 32 false false R33.htm 00000033 - Disclosure - NET LOSS PER SHARE (Details) Sheet http://atossagenetics.com/role/NetLossPerShareDetails NET LOSS PER SHARE (Details) Details http://atossagenetics.com/role/NetLossPerShareTables 33 false false R34.htm 00000034 - Disclosure - NET LOSS PER SHARE (Details 1) Sheet http://atossagenetics.com/role/NetLossPerShareDetails1 NET LOSS PER SHARE (Details 1) Details http://atossagenetics.com/role/NetLossPerShareTables 34 false false R35.htm 00000035 - Disclosure - CONCENTRATION OF CREDIT RISK (Details Narrative) Sheet http://atossagenetics.com/role/ConcentrationOfCreditRiskDetailsNarrative CONCENTRATION OF CREDIT RISK (Details Narrative) Details http://atossagenetics.com/role/ConcentrationOfCreditRisk 35 false false R36.htm 00000036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://atossagenetics.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://atossagenetics.com/role/CommitmentsAndContingencies 36 false false R37.htm 00000037 - Disclosure - STOCK BASED COMPENSATION (Details) Sheet http://atossagenetics.com/role/StockBasedCompensationDetails STOCK BASED COMPENSATION (Details) Details http://atossagenetics.com/role/StockBasedCompensationTables 37 false false R38.htm 00000038 - Disclosure - STOCK BASED COMPENSATION (Details 1) Sheet http://atossagenetics.com/role/StockBasedCompensationDetails1 STOCK BASED COMPENSATION (Details 1) Details http://atossagenetics.com/role/StockBasedCompensationTables 38 false false R39.htm 00000039 - Disclosure - STOCK BASED COMPENSATION (Details 2) Sheet http://atossagenetics.com/role/StockBasedCompensationDetails2 STOCK BASED COMPENSATION (Details 2) Details http://atossagenetics.com/role/StockBasedCompensationTables 39 false false R40.htm 00000040 - Disclosure - STOCK BASED COMPENSATION (Details 3) Sheet http://atossagenetics.com/role/StockBasedCompensationDetails3 STOCK BASED COMPENSATION (Details 3) Details http://atossagenetics.com/role/StockBasedCompensationTables 40 false false R41.htm 00000041 - Disclosure - STOCK BASED COMPENSATION (Details Narrative) Sheet http://atossagenetics.com/role/StockBasedCompensationDetailsNarrative STOCK BASED COMPENSATION (Details Narrative) Details http://atossagenetics.com/role/StockBasedCompensationTables 41 false false All Reports Book All Reports atos-20180630.xml atos-20180630.xsd atos-20180630_cal.xml atos-20180630_def.xml atos-20180630_lab.xml atos-20180630_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/us-gaap/2017-01-31 true true ZIP 59 0001615774-18-007923-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001615774-18-007923-xbrl.zip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end

Form of Instructions as to Use of Subscription Rights Certificates

Amendment No.2 to Registration Statement on Form S-1, as Exhibit 99.1

May 3, 2018

Form of Letter to Shareholders Who Are Record Holders

Amendment No.2 to Registration Statement on Form S-1, as Exhibit 99.2

May 3, 2018